Joint Meeting of the 20th ISSTDR and 14th IUSTI

STI & AIDS World Congress 2013 July 14-17 Vienna

Threatening past promising future

FINAL PROGRAMME
Achieve same-day detection and containment with Xpert CT/NG. In addition to single-test confidence for CT/NG, our full menu of fast, accurate and easy-to-use molecular tests helps you strengthen antibiotic stewardship, shrink patient stays, advance care, and reduce costs. Welcome to immediate informed decisions.

Cepheid powers same-day results in more than 3,000 locations worldwide. Learn more at cepheidinternational.com.
# TABLE OF CONTENTS

## GENERAL

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcoming Address</td>
<td></td>
</tr>
<tr>
<td>Committees</td>
<td></td>
</tr>
<tr>
<td>Boards</td>
<td></td>
</tr>
<tr>
<td>Congress Organisation</td>
<td></td>
</tr>
<tr>
<td>Acknowledgement Sponsors</td>
<td></td>
</tr>
<tr>
<td>Keynote Speaker, Plenary Speakers and Track Chairs</td>
<td></td>
</tr>
<tr>
<td>Floorplan</td>
<td></td>
</tr>
<tr>
<td>Programme at a Glance</td>
<td></td>
</tr>
</tbody>
</table>

## SCIENTIFIC PROGRAMME

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-Congress Programm – Sunday, July 14</td>
<td></td>
</tr>
<tr>
<td>Scientific Programme – Monday, July 15</td>
<td></td>
</tr>
<tr>
<td>Scientific Programme – Tuesday, July 16</td>
<td></td>
</tr>
<tr>
<td>Scientific Programme – Wednesday, July 17</td>
<td></td>
</tr>
<tr>
<td>Satellites Symposia</td>
<td></td>
</tr>
</tbody>
</table>

## INFORMATION

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Board Meetings and Side Meetings</td>
<td></td>
</tr>
<tr>
<td>Scientific Information – Posters and Oral Presentations</td>
<td></td>
</tr>
<tr>
<td>General Information – Registration, Networking Events</td>
<td></td>
</tr>
<tr>
<td>Exhibition Information – Exhibitors, Floorplan</td>
<td></td>
</tr>
</tbody>
</table>
WELCOME TO THE STI & AIDS WORLD CONGRESS 2013 IN VIENNA!

Dear Friends and Colleagues,

We take great pleasure in welcoming you to the STI & AIDS World Congress 2013 in Vienna on behalf of the Boards and Executive Committees of both, the International Society for Sexually Transmitted Diseases Research (ISSTDR) and the International Union against Sexually Transmitted Infections (IUSTI).

This is the first time that the ISSTDR has decided to hold its biennial conference in Vienna and it is a special privilege to organize the 20th Meeting of the ISSTDR as the 4th joint meeting with the 14th World Congress of the IUSTI. This meeting marks also the 90th year of the foundation of IUSTI and will give us a reason for a special celebration.

Vienna, located in the centre of Europe, has a tradition for a major conference site at least since the year 1815, when the city hosted the peace talks following the Napoleon Wars with the historic sentence “The congress dances in the Vienna Hofburg”. Vienna has established an outstanding reputation as conference city and ranks on the top of congress destinations of the world. As a former imperial city with a modern flair, Vienna offers an excellent setting for meetings, optimally combining art treasures, music, and enjoyment. We have chosen for this congress the most attractive conference venue, the Vienna Hofburg, the former Winter Palace of the Habsburg Emperors.

This conference provides one of the best opportunities for clinicians and scientists to present and discuss the latest developments in STI and AIDS. Under the guidance of the Chair and the Members of the International Scientific Committee the scientific programme is of highest quality with a wide range of important topics from research to clinical practice. We are impressed by the high interest in this conference: more than 1300 abstracts were submitted by delegates from more than 100 countries of which about 150 were selected for oral presentations and close to 1000 as posters. The oral presentations and symposia reflect research of the area of all six scientific tracks and are supplemented by plenary lectures and debates on innovative topics. The last session will summarize the main research results by experts of the scientific tracks for all participants who had not the chance to follow all lectures in the parallel sessions.

We believe that the programme presents the best from both organisations – a strong commitment to basic science as well as a clear focus on translational efforts to ensure that our discussions remain pertinent to the pressing problems of STI cure and containment. The conference theme “Threatening Past - Promising Future” encapsulates our hopes for the meeting.

STIs disproportionately impact the developing world and the organizers - through the programme and scholarship committees - have made efforts to ensure truly global participation and to foster new talents through encouraging attendance by young researchers, an important priority for our field. About 60 out of more than 250 applications were selected by the scholarship committee and are attending with the support of travel grants, funded by a generous contribution from the Office of AIDS Research, National Institute of Health. We are thankful to the Centers for Disease Control, USA, and the WHO for their contribution and donations as well as to numerous companies and local governmental agencies.

We also wish to thank the many individuals from the ISSTDR and IUSTI Boards, the Local Organizing and the International Scientific Committee who dedicated energy and time to make this meeting successful.

We hope that you will find the conference intellectually and socially rewarding and invite you to participate in the scientific programme, the opening ceremony and the Gala Dinner at the Vienna City Hall. “The congress dances in the Vienna Hofburg”

Join us in Vienna for what promises to be a wonderful event!

Angelika Stary
Congress Chair
ISSTDR President

Raj Patel
Congress Co-chair
IUSTI President
COMMITTEES

CONGRESS ORGANISING COMMITTEE
Congress Chair of the STI & AIDS World Congress 2013:
Angelika Stary, Vienna, Austria
Raj Patel, Southampton, United Kingdom

INTERNATIONAL SCIENTIFIC COMMITTEE

Chair: Thomas Quinn,
Baltimore, Maryland, USA

01 Basic Sciences Track
Myron Cohen
Jorgen Jensen
David Lewis
Sheila Lukehart
Anna Wald

02 Clinical Sciences Track
Roy Chan
Jorma Paavonen
Keith Radcliffe
Jane Schwebke
Janet Wilson

03 Epidemiology and Prevention Sciences Track
Ward Cates
Patricia Garcia
Sharon Hillier
Jeanne Marrazzo
Nancy Padian

04 Social and Behavioral Sciences Track
Sevgi Aral
Thomas Coates
Jonathan Ellen
Carl Latkin
Helen Ward

05 Translational and Implementation Sciences Track
Gail Bolan
Max Chernesky
Christopher Fairley
Charlotte Gaydos
Cornelius Rietmeijer
Julius Schachter

06 Health Policy and Program Sciences Track
James Blanchard
Kevin Fenton
Geoffrey Garnett
King Holmes
Jonathan Ross

LOCAL ORGANISING COMMITTEE

Board of the Austrian Society for Sexually Transmitted Diseases and Dermatological Microbiology
Alexandra Geusau
Gabriele Ginter-Hanselmayer
Gudrun Heidler
Claudia Heller-Vitouch
Reinhard Höpfl
Reinhard Kirnbauer
Peter Komericki
Angelika Stary
Josef Söltz-Szöts †
Georg Stingl
Erwin Tschachler

SCHOLARSHIP COMMITTEE
Chair: David Lewis, Sandringham, South Africa
Jo-Anne Dillon, Saskatoon, Canada
Charlotte Gaydos, Baltimore, United States

INFORMATION SATELLITE SYMPOISAS

GENERALSUNDAYMONDAYTUESDAYWEDNESDAY
INTERNATIONAL SOCIETY FOR STD RESEARCH (ISSTDR)

Board Members:

Angelika Stary, President and Chair of 20th Meeting, 2013 (Vienna, Austria)
Basil Donovan, President Elect and Chair of the 21st Meeting, Brisbane, 2015 (Sydney, Australia)
Michel Alary, Immediate Past President and Chair, 19th Meeting, 2011 (Québec, Canada)
Catherine Ison, Past President and Chair, 18th Meeting, 2009 (London, United Kingdom)
Henry De Vries (Amsterdam, The Netherlands)
Charlotte A. Gaydos (Baltimore, United States)
Matthew Golden (Seattle, United States)
Graham J. Hart (London, United Kingdom)
Jacky M. Jennings (Baltimore, United States)
David A. Lewis (Sandringham, South Africa)
Jeanne Marrazzo (Seattle, United States)
Barbara Van Der Pol (Indianapolis, United States)
Magnus Unemo (Örebro, Sweden)

INTERNATIONAL UNION AGAINST SEXUALLY TRANSMITTED INFECTIONS (IUSTI) EXECUTIVE COMMITTEE

Office Bearers:

Raj Patel, Southampton, UK (President)
David A Lewis, Johannesburg, South Africa (President-Elect)
Janet Wilson, Leeds, UK (Secretary General)
Immy Ahmed-Jushuf, Nottingham, UK (Treasurer)
Christopher Fairley, Melbourne, Australia (Assistant Secretary General)
King Holmes, Seattle, USA (Immediate Past President)
Somesh Gupta, New Delhi, India (Membership Secretary)
Jonathan Ross, Birmingham, UK (Editor - STI Global Update)

Elected Executive Committee Members:

Yaw Adu-Sarkodie, Kumasi, Ghana
Xiang-sheng Chen, NanJing, China
Marco Cusini, Milan, Italy
Jo-Anne Dillon, Saskatoon, Canada
John Douglas, Atlanta, USA
Amina Hançali, Rabat, Morocco
Michel Janier, Paris, France
Chavalit Mangkalaviraj, Bangkok, Thailand
Sam Phiri, Lilongwe, Malawi
Darren Russell, Cairns, Australia
Mihael Skerlev, Zagreb, Croatia
Miguel Tili, Buenos Aires, Argentina
Freddy Tinajeros, Tegucigaipa, Honduras

Observers:

Gail Bolan, Liaison, Centers for Disease Control and Prevention (CDC), (Atlanta, United States)
Raj Patel, Liaison, International Union against Sexually Transmitted Infections (IUSTI), (Southampton, United Kingdom)

Regional Directors:

Roy Chan, Asia-Pacific
Patricia Garcia, Latin-America
Charlotte Gaydos, North America
David A Lewis, Africa
Keith Radcliffe, Europe

Observers:

Gail Bolan, Liaison, Centers for Disease Control and Prevention (CDC), (Atlanta, United States)
Raj Patel, Liaison, International Union against Sexually Transmitted Infections (IUSTI), (Southampton, United Kingdom)
**IUSTI EUROPEAN ADVISORY BOARD**

Executive Board and Council Members of IUSTI-Europe

Regional Director: **Keith Radcliffe** (UK)
Chair: **Airi Poder** (Estonia)
Secretary: **Claudia Heller-Vitouch** (Austria)
Treasurer: **Mikhail Gomberg** (Russia)
Membership Secretary: **Jackie Sherrard** (UK)

Senior Counsellor: **David Barlow** (UK)

### National Representatives:

- Uladzimir Adaskevich (Belarus)
- Immy Ahmed (UK)
- Karen Babayan (Armenia)
- Mircea Betsiu (Moldova)
- Norbert Brockmeyer (Germany)
- Krasimira Chudomirova (Bulgaria)
- Marco Cusini (Italy)
- Gilbert Donders (Belgium)
- Vugar Eyvazov (Azerbaijan)
- Candida Fernandes (Portugal)
- Dan Forsea (Romania)
- Derek Freedman (Eire)
- Deniz Gokengin (Turkey)
- Mikhail Gomberg (Russia)
- Eija Hiltunen-Back (Finland)
- Michel Janier (France)
- Andrzej Klepacki (Poland)
- Josephe Kobakhidze (Georgia)
- Vesta Kučinskienė (Lithuania)
- Stefan Lautenschlager (Switzerland)
- Juraj Pec Martin (Slovakia)
- Gennadiy Mavrov (Ukraine)
- Harald Moi (Norway)
- Karoly Nagy (Hungary)
- Electra Nikolaidou (Greece)
- Joseph Pace (Malta)
- Airi Poder (Estonia)
- Marko Potocnik (Slovenia)
- Andris Y. Rubins (Latvia)
- Mihael Skerlev (Croatia)
- Joergen Skov Jensen (Denmark)
- Angelika Stary (Austria)
- Marti Vall Mayans (Spain)
- Willem I. Van der Meijden (The Netherlands)
- Karl Arne Wikström (Sweden)

### Past ISSTDR Presidents and Congress Locations

<table>
<thead>
<tr>
<th>Meeting</th>
<th>Date</th>
<th>Location</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st Meeting</td>
<td>1977</td>
<td>Rotterdam, The Netherlands</td>
<td>Ernst Stoltz</td>
</tr>
<tr>
<td>2nd Meeting</td>
<td>1979</td>
<td>Helsinki, Finland</td>
<td>Alan Lassus</td>
</tr>
<tr>
<td>3rd Meeting</td>
<td>1980</td>
<td>Antwerp, Belgium</td>
<td>Peter Piot</td>
</tr>
<tr>
<td>4th Meeting</td>
<td>1981</td>
<td>Heidelberg, Germany</td>
<td>Detlef Petzoldt</td>
</tr>
<tr>
<td>5th Meeting</td>
<td>1983</td>
<td>Seattle, United States</td>
<td>King K. Holmes</td>
</tr>
<tr>
<td>6th Meeting</td>
<td>1985</td>
<td>Brighton, United Kingdom</td>
<td>JRW Harris</td>
</tr>
<tr>
<td>7th Meeting</td>
<td>1987</td>
<td>Atlanta, United States</td>
<td>Sumner E. Thompson</td>
</tr>
<tr>
<td>8th Meeting</td>
<td>1989</td>
<td>Copenhagen, Denmark</td>
<td>Inga Lind</td>
</tr>
<tr>
<td>9th Meeting</td>
<td>1991</td>
<td>Banff, Canada</td>
<td>Allan Ronald</td>
</tr>
<tr>
<td>10th Meeting</td>
<td>1993</td>
<td>Helsinki, Finland</td>
<td>Jorma Paavonen</td>
</tr>
<tr>
<td>11th Meeting</td>
<td>1995</td>
<td>New Orleans, United States</td>
<td>D. H. Martin</td>
</tr>
<tr>
<td>12th Meeting</td>
<td>1997</td>
<td>Seville, Spain</td>
<td>Evelio Perea – 1st Joint ISSTDR-IUSTI Meeting</td>
</tr>
<tr>
<td>13th Meeting</td>
<td>1999</td>
<td>Denver, United States</td>
<td>Franklyn N. Judson</td>
</tr>
<tr>
<td>14th Meeting</td>
<td>2001</td>
<td>Berlin, Germany</td>
<td>Peter Kohl – 2nd Joint ISSTDR-IUSTI Meeting</td>
</tr>
<tr>
<td>15th Meeting</td>
<td>2003</td>
<td>Ottawa, Canada</td>
<td>Jo-Anne Dillon</td>
</tr>
<tr>
<td>16th Meeting</td>
<td>2005</td>
<td>Amsterdam, The Netherlands</td>
<td>Roel Coutinho</td>
</tr>
<tr>
<td>17th Meeting</td>
<td>2007</td>
<td>Seattle, United States</td>
<td>H. Hunter Handsfield – 3rd Joint ISSTDR-IUSTI Meeting</td>
</tr>
<tr>
<td>18th Meeting</td>
<td>2009</td>
<td>London, United Kingdom</td>
<td>Catherine Ison</td>
</tr>
<tr>
<td>19th Meeting</td>
<td>2011</td>
<td>Québec, Canada</td>
<td>Michel Alary</td>
</tr>
</tbody>
</table>
Anthony S. Fauci, M.D., is director of the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health. Dr. Fauci also is chief of the NIAID Laboratory of Immunoregulation, where he has made numerous important discoveries related to HIV/AIDS. He was one of the principal architects of the President’s Emergency Plan for AIDS Relief (PEPFAR), which has already been responsible for saving millions of lives throughout the developing world. Dr. Fauci is a member of the US National Academy of Sciences and is the recipient of numerous prestigious awards including the National Medal of Science, the Mary Woodard Lasker Award for Public Service, and the Presidential Medal of Freedom. He is the author, coauthor, or editor of more than 1,200 scientific publications, including several major textbooks.

Sevgi O. Aral, PhD, MA, MS holds Professorial appointments at the University of Washington in Seattle, University of Manitoba in Winnipeg, and Emory University in Atlanta. Dr. Aral came to the Centers for Disease Control and Prevention from Middle East Technical University in Ankara, Turkey where she was the chair of the Department of Social Sciences. Dr. Aral has authored more than 230 scientific articles and edited 16 journal issues and 2 books. She has served on many national and international work groups, boards and committees; and has consulted for the World Health Organization, the European Union and the World Bank. She has also received the ASTDA Achievement Award and the Thomas Parran Award. Dr. Aral’s research interests have included social and behavioral aspects of sexually transmitted disease, epidemiology and prevention; including gender, age and race effects; mixing patterns; sexual and social networks; contextual factors; social determinants and most recently, program science.

Jared Baeten's research focuses on epidemiologic studies of HIV/STI transmission and clinical trials of novel HIV prevention interventions. He co-chairs the Partners PrEP Study, which demonstrated that emtricitabine/tenofovir pre-exposure prophylaxis (PrEP) provided 75% protection against heterosexual HIV acquisition. Linked projects include a large observational study of PrEP adherence and laboratory analyses of innate and adaptive immune responses related to PrEP. Other current projects include a) a multinational phase III trial of dapivirine vaginal ring for HIV prevention in women (MTN-020/ASPIRE, through the NIH Microbicides Trials Network, study chair), b) implementation studies of combination HIV prevention in South Africa and Uganda, c) epidemiologic studies exploring use of hormonal contraception as an HIV risk factor, and d) demonstration projects to deliver antiretroviral treatment and PrEP for HIV prevention in African HIV serodiscordant couples.

Willard Cates, Jr., M.D., M.P.H. is Distinguished Scientist and President Emeritus at FHI 360. Before joining FHI 19 years ago, Dr. Cates spent two decades at the Centers for Disease Control and Prevention, where he directed STD/HIV prevention efforts and helped lead family planning evaluation activities. Dr. Cates has authored or co-authored more than 450 scientific publications. He is a Member of the Institute of Medicine and the American College of Preventive Medicine. He serves as Adjunct Professor of Epidemiology at the University of North Carolina Gillings School of Global Public Health and Clinical Professor in UNC’s Department of Medicine.

Dr. Xiang-Sheng Chen is a professor of the Peking Union Medical College and Vice Director of the National Center for STD Control in China. He is a member of the Expert Advisory Panel for Disease Control of the National Health and Family Planning Commission (NHFPCC) of China and one of leading experts to lead many STD control projects in China. He is also an executive committee member of the International Union against Sexually Transmitted Infections (IUSTI), and an adjunct professor of the University of North Carolina (UNC) School of Medicine at Chapel Hill.

Dr. Franco is a cancer epidemiologist at McGill University, Montreal, where he is Professor and Chair, Department of Oncology, and Director, Division of Cancer Epidemiology. He published over 360 articles, 55 chapters, and two books. He is the Editor-in-Chief of Preventive Medicine and has served in the editorial boards of several journals. His distinctions include: Fellow of the Canadian Academy of Health Sciences (2012), Fellow of the Royal Society of Canada (2011), Lifetime Achievement Award, American Society for Colposcopy and Cervical Pathology (2010), Women in Government’s Leadership Award (2008), Canadian Cancer Society’s Warwick Prize (2004), Medical Research Council’s Distinguished Scientist Award (2000), and Educational Excellence at McGill (2000).

Dr. Gaydos is a Professor in the Division of Infectious Diseases, Johns Hopkins University, Director of the North American Branch for the International Union Against Sexually Transmitted Infections, and member of the Center for Global Health. She is the Director of the International STI, Respiratory Diseases, and Biothreat Research Laboratory. She has 45 years laboratory expertise in microbiology, has authored 22 book chapters, 320 research articles, and >500 abstracts/oral presentations. Dr. Gaydos has conducted clinical trials for new diagnostics for STIs and respiratory pathogens and developed multiple DNA amplification tests. Internet recruitment of home-collected samples for STI screening has been an effective outreach program. Her CLIA-licensed laboratory is the Core Diagnostic/Reference Laboratory for international studies of STIs, respiratory diseases, and tuberculosis. She is Diagnostic Core Co-investigator for the Mid-Atlantic Center of Excellence for Biothreat and Emerging Diseases and PI of an NIH Center grant to develop point-of-care tests for STIs.
King Holmes

Dr. King Holmes chairs the Department of Global Health; he is the Director of the University of Washington Center for AIDS and STDs, a WHO Collaborating Center, and Principle Investigator for the NIH-funded UW/FHCRC Center for AIDS Research which has over 550 members, including faculty, research scientists, and pre- and post-doctoral fellows. He is also PI for the UW International Training and Education Center on Health (I-TECH), with HIV-related programs in 20 countries throughout the world. Dr. Holmes has participated in research on STIs for 45 years and in research, training, and technical assistance on HIV/AIDS and other STIs in Africa, Latin America, SE Asia, and the Western Pacific for over 25 years. He has participated in the design and conduct of 40 randomized controlled trials of STI treatment and prevention. His research has addressed the clinical epidemiology, pathogenesis, diagnosis, treatment, and prevention of bacterial, viral, and other STIs and STI-related clinical syndromes. He has trained and/or mentored over 100 scientists involved in HIV/STI research and care in the U.S. and other countries throughout the world.

Sheila A. Lukehart

Sheila A. Lukehart, Ph.D. is Professor of Medicine and Global Health at the University of Washington in Seattle, WA. She is a recognized expert on syphilis and Treponema pallidum, and was awarded the 2007 Thomas Parran Award from the American STD Association in recognition of her contributions to STD research. Dr. Lukehart has focused her research on molecular pathogenesis of syphilis, host immune responses to Treponema pallidum, neurosyphilis, syphilis-HIV interactions, and antibiotic resistance in T. pallidum. Dr. Lukehart has been actively involved in the training of young STD scientists and directs the University of Washington STD & AIDS Research Training Program.

Kenneth Mayer

Prof. Mayer’s clinical research career has focused on the natural history and transmission of HIV in the US and in Asia. Dr. Mayer is currently a Professor at Harvard Medical School and Attending Physician and Director of HIV Prevention Research at Beth Israel Deaconess Hospital in Boston. As the founding Medical Research Director of Fenway Health, he created a community health research program that has developed an international reputation for its capability to conduct community-based peer reviewed research.

Thomas Quinn

Dr. Thomas Quinn is Senior Investigator and Head of the Section on International HIV/AIDS Research in the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases. He is also Associate Director for International Research for the Division of Intramural Research at NIAID. He is the Director of the Center for Global Health, and is Professor of Medicine and International Health at The Johns Hopkins University. His research interests have involved laboratory investigations that have helped define the biological factors involved in sexual and perinatal transmission of HIV, the natural history and treatment of HIV infections, and the molecular epidemiology of HIV. He is a member of the Institute of Medicine and Fellow of the American Association for the Advancement of Science. He is an author of over 900 publications on HIV, STDs, and infectious diseases.

Georg Stingl

Dr. Stingl has contributed greatly to our understanding of the skin as an immune organ under physiologic and pathologic (e.g. psoriasis, atopic dermatitis, syphilis, HIV-infection) conditions. His major accomplishments include the discovery of Langerhans cells as immunocytes and of the indigenous T cell population of rodent skin. In the recent years, his research group has elucidated the mode of action of several immunomodulatory drugs. He is a member of the board of several scientific societies and organizations, advisory panels, scientific journals and committees, including honorary membership of the two leading societies of dermatological research, i.e. The Society for Investigative Dermatology and the European Society for Dermatological Research and membership of the Presiding Committee of the Austrian and the German Academy of Sciences.

Magnus Unemo

Dr. Magnus Unemo, Ph.D. and Assoc Professor in Medical Microbiology and Molecular Biology, is directing the WHO Collaborating Centre for Gonorrhoea and Other STIs and the Swedish Reference Laboratory for Neisseria gonorrhoeae at Örebro University Hospital, Sweden. He is also serving ECDC in numerous projects, is included in the ECDC STI Reference Laboratory hub for EU countries and is a member of the Editorial Board for the European STI Guidelines. His main research focuses on N. gonorrhoeae and other bacterial STIs, and he has published more than 170 peer-reviewed scientific papers and many chapters in international STI books.

David Wilson

David Wilson is the World Bank’s Global AIDS Program Director and was previously the Bank’s Lead HIV Specialist. His work on HIV/AIDS spans almost 25 years. During his career he has worked as a scientist and program manager in over 50 countries and published approximately 100 scientific papers. He has developed prevention programs that have been recognized as best practice by the World Bank, WHO and DFID, and have been influential in international HIV prevention science. In addition, he has served as technical consultant and adviser to many international agencies, including USAID, DFID, EU, AUSAID, SIDA, NORAD, UNAIDS, UNICEF and WHO.
Full automation for Sexually Transmitted Disease screening

HBsAg Quant · HCV Ab · HIV Ab/Ag
Treponema Screen · Chlamydia IgA/IgG

LIAISON®
Innovation to meet your needs
01 Basic Sciences Track
Chair: Sheila Lukehart
The Basic Science track will feature invited speakers in three Symposia:
- Bacterial Virulence and Host Response
- Molecular Mechanisms of Antimicrobial Resistance
- STD Vaccines and Correlates of Immunity
Oral sessions on Microbial Virulence and Host Response, Antimicrobial Resistance Mechanisms in STI Pathogens, and Molecular Analysis of STI Pathogens and their Environments will highlight selected abstracts. Poster Sessions include a variety of basic science posters that will be available for viewing and discussion with the authors.

02 Clinical Sciences Track
Chair: Keith Radcliffe
It is a pleasure and an honour to have played a part in selecting the material for the clinical track at this conference. A wide range of topics are covered but certain themes loom large, such as the role of new diagnostic technologies and the impact of vaccination against HPV. There are also new insights into long recognised syndromes such as bacterial vaginosis, urethritis, proctitis and salpingitis. The problem of increasing antimicrobial resistance, especially in gonorrhoea, also receives a lot of attention and deservedly so. Overall the content reflects the fascinating and ever changing nature of this branch of medicine. I hope that you enjoy it.

03 Epidemiology and Prevention Sciences Track
Chair: Jeanne Marrazzo
The Epidemiology and Prevention track at ISSTD will feature research that reports on important communications in the epidemiology of common sexually transmitted infections, including genital herpes, genital human papillomavirus, HIV, chlamydia and gonococcal infections, and trichomoniasis. New data on emerging pathogens and their environments, including Mycoplasma genitalium and the genital microbiome, may also be featured. This track will also include important research findings from studies that have aimed to prevent these important infections, particularly using biomedical approaches.

04 Social and Behavioral Sciences Track
Chair: Sevgi Aral
The Social and Behavioral Science Track covers recent scientific information on social determinants of STIs; behavioral risk factors for STI acquisition and transmission; and structural and behavioral interventions aiming to decrease STI transmission and acquisition at both the individual and population levels. The track also covers synergistic and antagonistic interactions among social and behavioral interventions as well as interactions between interventions and the social/epidemiological context they are introduced into.

05 Translational and Implementation Sciences Track
Chair: Charlotte Gaydos
The Translational and Implementation Science Tract will provide new scientific findings on ways that research results from basic science, behavioural and treatment interventions, vaccine uptake, diagnostic assays, and laboratory issues are executed in order to provide the best clinical care for patients. Application and implementation of research interventions, best practice guidelines, and new diagnostic paradigms can provide real-world practical evaluations and clinical sustainability of research results in actual practice. Translating research from the “bench to the bedside” will ultimately provide the best clinical management for patients with sexually transmitted infections.

06 Health Policy and Program Sciences Track
Chair: James Blanchard
The past two decades have seen the emergence of a range of new technologies and interventions for the prevention, diagnosis and treatment of sexually transmitted infections (STIs). Despite these advances, curtailing and reversing STI epidemics remains a considerable public health challenge. In particular, scientific approaches are required to better assess epidemics and focus programs accordingly, selecting and combining interventions appropriately, and managing and evaluating programs as they are scaled up. The newly introduced Health Policy and Programme Sciences track will focus on these emerging opportunities and challenges, and highlight examples of how science can better contribute to STI programs.
Conference Organisation
Registration and Abstract Management, Sponsoring, Corporate Satellites

STI & AIDS World Congress 2013
c/o Vienna Medical Academy
Ms. Alissa McGregor
Alser Strasse 4, A-1090 Vienna, Austria
T: 0043 1 405 13 83 11
F: 0043 1 407 82 74
E: STIvienna2013@medacad.org
www.medacad.org

Exhibition Management

MAW - Medizinische Ausstellungs- und Werbegesellschaft
Maria Rodler & Co GmbH
Ms. Simone Biach
Ms. Katrin Doppler
Freyung 6, A-1010 Vienna, Austria
T: 0043 1 536 63-37 or 76
F: 0043 1 535 60 16
E: maw@media.co.at

Hotel Accommodation

Mondial Congress & Events
Mondial GmbH & Co. KG
Ms. Barbara Obritzhauser, MA
Operngasse 20b, A-1040 Vienna, Austria
T: 0043 1 58804-172
F: 0043 1 58804-185
E: obritzhauser@mondial-congress.com
www.mondial-congress.com
CONTRIBUTORS, SPONSORS

The STI & AIDS World Congress gratefully acknowledges the support of the following institutions, companies and organisations (as per date of printing June 2013)

Major Contributors
American Sexually Transmitted Diseases Association (ASTDA)
Centers for Disease Control and Prevention (CDC)
European Centre for Disease Control (ECDC)
NIH Office for AIDS Research (OAR)
Österreichische Gesellschaft für Dermatologie und Venerologie (ÖGDV)
Prof. Josef Sölte Szöts
Vienna Convention Bureau
World Health Organisation (WHO)

Platinum sponsors

Gold sponsors

Silver sponsors

Bronze sponsors

Exclusive sponsors

Sponsors
abbvie
Almirall
bioMerieux Austria GmbH
eintegrity
Erste Bank
Qiagen
Pelpharma Handels GmbH
Sage Publication Ltd.
### SUNDAY, JULY 14, 2013

<table>
<thead>
<tr>
<th>ROOM</th>
<th>FESTSAAL</th>
<th>RITTERSAAL</th>
<th>GARTENSAAL</th>
<th>GEHEIME RATSTUBE</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td></td>
<td></td>
<td></td>
<td>(13:00 - 15:15) Symposium Joint symposium of the ÖGSTD (Austrian Society of STI and Dermatological Microbiology) and DSTIG (German Society for STI)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Workshop WHO: New WHO STI Guidelines: Introduction and scaling up implementation, what does it take?</td>
<td>Symposium CDC and University of Manitoba Established and Emerging STD/HIV Interventions in Countries of the South and Countries of the North: The Program Science Perspective</td>
<td>(15:30 - 17:00) ASTDA Symposium «Young Investigators» Research in Progress: Highlights from The American STD Association Developmental Awards Program</td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
<td>(15:00 - 17:00) Symposium CDC and University of Manitoba Established and Emerging STD/HIV Interventions in Countries of the South and Countries of the North: The Program Science Perspective</td>
</tr>
<tr>
<td>17:30 - 19:30</td>
<td>Opening Ceremony</td>
<td></td>
<td></td>
<td>(15:30 - 17:00) ASTDA Symposium «Young Investigators» Research in Progress: Highlights from The American STD Association Developmental Awards Program</td>
</tr>
<tr>
<td></td>
<td>Opening Keynote Lecture</td>
<td></td>
<td></td>
<td>(15:30 - 17:00) ASTDA Symposium «Young Investigators» Research in Progress: Highlights from The American STD Association Developmental Awards Program</td>
</tr>
<tr>
<td>19:30 - 21:00</td>
<td>Networking Event</td>
<td></td>
<td></td>
<td>(15:30 - 17:00) ASTDA Symposium «Young Investigators» Research in Progress: Highlights from The American STD Association Developmental Awards Program</td>
</tr>
<tr>
<td></td>
<td>Welcome Reception</td>
<td></td>
<td></td>
<td>(15:30 - 17:00) ASTDA Symposium «Young Investigators» Research in Progress: Highlights from The American STD Association Developmental Awards Program</td>
</tr>
</tbody>
</table>

**Plenary Session**

**Debate**

**Symposium**

**Oral Session**

**Presented Posters**

**Satellites Symposia**

**Poster viewing**
## PROGRAMME AT A GLANCE

**MONDAY, JULY 15, 2013**

<table>
<thead>
<tr>
<th>ROOM</th>
<th>FESTSAAL</th>
<th>PRINZ EUGEN SAAL</th>
<th>ZEREMONIENSAAL</th>
<th>FORUM</th>
<th>RITERSAAL</th>
<th>GARTENSAAL</th>
<th>GEHEIME RATSTUBE</th>
<th>TRABANTENSTUBE</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:50 - 08:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30 - 09:30</td>
<td></td>
<td>Plenary Session 01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30 - 10:00</td>
<td>D.01 Effective STD control programs are essential to prevent HIV transmission within populations.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 - 10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 - 10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 - 12:00</td>
<td>S.01 Microbicides To Prevent HIV/STD 2013: An Update</td>
<td>S.02 Translating and Implementing the Results of Diagnostic Assay Evaluations: From the Research Laboratory to Patient Care</td>
<td>S.03 Advancing Prevention of Sexually Transmitted Infections through Sexual Health Promotion: Opportunities and Lessons Learned (organised by CDC/WHO/ECDC)</td>
<td>O.01 Microbial Virulence and Host Response</td>
<td>O.02 Antimicrobial Therapy for genital tract infections</td>
<td>O.03 Neisseria gonorrhoeae Resistance: Superbug ante portas?</td>
<td>O.04 Vaginal Infections and PID</td>
<td></td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td>SAT01 SEX, DRUGS and ROCK 'n' ROLL</td>
<td>Sponsored by Gilead Science GmbH</td>
<td>SAT02 Integrated Approaches in the Management of Sexually Transmitted Infections</td>
<td>SAT03 Comparison and Clinical Application of Instrumentation Platforms and Assays for STI Detection</td>
<td>Sponsored by Roche</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00 - 14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00 - 14:00</td>
<td>SAT01 SEX, DRUGS and ROCK 'n' ROLL</td>
<td>Sponsored by Gilead Science GmbH</td>
<td>SAT02 Integrated Approaches in the Management of Sexually Transmitted Infections</td>
<td>Sponsored by Roche</td>
<td>SAT03 Comparison and Clinical Application of Instrumentation Platforms and Assays for STI Detection</td>
<td>Sponsored by Roche</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00 - 15:30</td>
<td>S.04 Scaling up of HIV treatment programs among the most at-risk populations in low- and middle-income countries</td>
<td>S.05 Fostering an integrated Approach to the Control of Antimicrobial Resistance in Neisseria gonorrhoeae (organised by WHO)</td>
<td>S.06 Clinical Issues and Potential Solutions</td>
<td>O.05 Molecular Analysis of STI Pathogens and their Environments</td>
<td>O.06 Sexually Transmitted Infections: Social and Behavioural Determinants and Consequences</td>
<td>O.08 Get those partners treated</td>
<td>O.09 Programme implementation and scaling up</td>
<td></td>
</tr>
<tr>
<td>15:30 - 16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00 - 17:30</td>
<td></td>
<td>Plenary Session 02</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30 - 18:00</td>
<td>D.02 Social and behavioural interventions are no longer a priority in HIV prevention programmes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00 - 19:00</td>
<td>Poster viewing with authors</td>
<td>SAT04 Bacterial STIs in Europe (organised by Astellas Pharma Europe BV)</td>
<td>SAT05 Molecular Diagnostics: A Syndromic Approach to STI &amp; Vaginitis Testing</td>
<td>Where should Trichomonas vaginalis be included?</td>
<td>Sponsored by BD Diagnostics</td>
<td>Poster viewing with authors</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Plenary Session 01**
- **Debate**
- **Symposium**
- **Oral Session**
- **Presented Posters**
- **Satellites Symposia**
- **Poster viewing**
**TUESDAY, JULY 16, 2013**

<table>
<thead>
<tr>
<th>ROOM</th>
<th>FESTSAAL</th>
<th>PRINZ EUGEN SAAL</th>
<th>ZEREMONIENSAAL</th>
<th>FORUM</th>
<th>RITTERSAAL</th>
<th>GARTENSAAL</th>
<th>GEHEIME RATSTUBE</th>
<th>TRABANTENSTUBE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>07:50 - 08:30</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30 - 10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Plenary Session 03:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Anton Luger Memorial</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>10:00 - 10:30</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>10:30 - 12:00</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SAT06 How Does Your Partner Know?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SAT06 STI/HIV Treatment Guidelines: Important Areas of Clinical Uncertainty</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S07 Bacterial Virulence and Host Response</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>O10 HPV: genital tract malignancy and vaccination</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>O11 HIV Prevention and lessons learned from trials of HIV Pre-exposure Prophylaxis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>O12 Social Determinants and Structural Interventions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>O13 Epidemic appraisal and strategic planning</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>12:00 - 13:00</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>13:00 - 14:00</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SAT06 Quadrivalent Vaccine Symposium: Optimizing Strategies for Protecting Girls and Boys Against HPV Cancers and Other Related Diseases Sponsored by MSD/SPMSD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SAT07 Xpert® CT/NG: Molecular Testing for Control</td>
<td>Sponsored by Cepheid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>14:00 - 15:30</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SAT08 Molecular Mechanisms of Antimicrobial Resistance</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S10 HPV Treatment as Prevention</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S11 National Trends in Sexual Behavior: USA, UK and Switzerland</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>O14 Clinical Syndromes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>O15 For Lab Rats and other Nice and Mice</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>O16 STI: Robert - Clamydia, HPV, Special populations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>O17 Programme evaluation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>15:30 - 16:00</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>16:00 - 17:30</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Plenary Session 04</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D03 Adolescent and Neonatal Circumcision Should Be Promoted Globally for HIV Control</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>17:30 - 18:00</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>18:00 - 19:00</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Poster viewing</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Poster viewing with authors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>19:30</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Congress Evening</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ROOM</td>
<td>FESTSAAL</td>
<td>PRINZ EUGEN SAAL</td>
<td>ZEREMONIENSAAL</td>
<td>FORUM</td>
<td>RITTERSAAL</td>
<td>GARTENSAAL</td>
<td>GEHEIME RATSTUBE</td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td>----------</td>
<td>------------------</td>
<td>----------------</td>
<td>-------</td>
<td>------------</td>
<td>------------</td>
<td>------------------</td>
<td></td>
</tr>
<tr>
<td>07:50 - 08:30</td>
<td>Hot Topics: Selected Poster Discussions 03</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30 - 09:30</td>
<td>Pleanary Session 05</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30 - 10:00</td>
<td>D.04 Population-Based Screening for Chlamydia in Asymptomatic Women based on Age Should Be Abandoned</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 - 10:30</td>
<td>Coffee break / Exhibition / Poster viewing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 - 12:00</td>
<td>S.13 Challenges to a Comprehensive Approach to the Prevention of HIV and STI among Men who have Sex with Men in Europe (organised by ECDC)</td>
<td>S.12 STD Vaccines and Correlates of Immunity</td>
<td>S.14 New strategies and implementation of best practices for dual elimination of mother-to-child transmission of syphilis and HIV (organised by WHO)</td>
<td></td>
<td>O.18 Diagnosis of sexually transmitted infections</td>
<td>O.19 Prevention and Curing STIs: Who is the Winner?</td>
<td>O.20 Sexual Partnerships and Networks</td>
<td></td>
</tr>
<tr>
<td>12:00 - 13:30</td>
<td>Redoutensaal: The American STD Association Awards Luncheon and Lecture</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30 - 15:00</td>
<td>S.15 Sexual Networks and Contagion (Insights from phylodynamic studies, behaviour diffusion, social media studies)</td>
<td>S.16 Challenging Clinical Conditions</td>
<td>O.21 Antimicrobial Resistance Mechanisms in STI Pathogens</td>
<td>O.22 Alternative screening tools and screening sites</td>
<td>O.23 Risk Behaviors and Preventive Interventions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00 - 16:30</td>
<td>S.17 Scientific Tracks: Summary and Highlights</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30 - 16:45</td>
<td>Closing Remarks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SUNDAY, JULY 14, 2013

SCIENTIFIC
PRE-Congress
Programme
A powerful combination – you and Roche
Meeting STD diagnostic and screening demands together

Reduce the burden
The case for early and prompt diagnosis of sexually transmitted infection is overwhelming; early treatment and care contribute to the overall global control of sexually transmitted infections.

Increase lab efficiency
STD patient management based on rapid, definitive test results can have lasting impact both medically and economically. This is a winning combination for patients, labs and the community.

Proven product solutions
- **HPV**: Differentiating patients at highest risk for cervical cancer progression with 16 and 18 HPV genotyping as well as broad high risk coverage
- **CT/NG**: Innovative assay design reduces equivocals and repeats
- **HSV 1 and 2**: Complete screening solution of symptomatic and asymptomatic patients for HSV 1 and 2 including serology and genotyping
- **HBV**: A complete solution from screening to treatment monitoring
- **HIV**: Comprehensive solution covering all stages of disease detection, progression and disease management

For more information, visit the Roche booth
or go to www.roche.com

* LightCycler® HSV 1/2 Qualitative Test is not available in the US
Roche Elecsys HSV-1 IgG and HSV-2 IgG immunoassays are FDA approved.
A powerful combination – you and Roche
Meeting STD diagnostic and screening demands together

• HPV:
  Differentiating patients at highest risk for cervical cancer progression with 16 and 18 HPV genotyping as well as broad high risk coverage

• CT/NG:
  Innovative assay design reduces equivocals and repeats

• HSV 1 and 2*:
  Complete screening solution of symptomatic and asymptomatic patients for HSV 1 and 2 including serology and genotyping

• HBV:
  A complete solution from screening to treatment monitoring

• HIV:
  Comprehensive solution covering all stages of disease detection, progression and disease management

Reduce the burden
Increase lab efficiency
Proven product solutions

For more information, visit the Roche booth or go to www.roche.com

The case for early and prompt diagnosis of sexually transmitted infection is overwhelming; early treatment and care contribute to the overall global control of sexually transmitted infections. STD patient management based on rapid, definitive test results can have lasting impact both medically and economically. This is a winning combination for patients, labs and the community.

* LightCycler® HSV 1/2 Qualitative Test is not available in the US

Roche Elecsys HSV-1 IgG and HSV-2 IgG immunoassays are FDA approved.

SUNDAY, JULY 14, 2013

<table>
<thead>
<tr>
<th>ROOM</th>
<th>FESTSAAL</th>
<th>RITTERSAAL</th>
<th>GARTENSAAL</th>
<th>GEHEIME RATSTUBE</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td></td>
<td>Workshop WHO: New WHO STI Guidelines: Introduction and scaling up implementation, what does it take?</td>
<td>Symposium CDC and University of Manitoba Established and Emerging STD/AIDS Interventions in Countries of the South and Countries of the North: The Program Science Perspective</td>
<td>(13:00 - 15:15) Symposium Joint symposium of the ÖGSTD (Austrian Society of STI and Dermatological Microbiology) and DSTIG (German Society for STI) (15:30 - 17:00) ASTDA Symposium «Young Investigators» Research in Progress: Highlights from The American STD Association Developmental Awards Program</td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>17:30 - 19:30</td>
<td>Opening Ceremony Opening Keynote Lecture</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>19:30 - 21:00</td>
<td>Networking Event Welcome Reception</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Plenary Session Debate Symposium Oral Session Presented Posters Satellites Symposia Poster viewing
PRE-CONGRESS PROGRAMME

SUNDAY, JULY 14, 2013

09:00 – 17:00

Room: Rittersaal

WHO Workshop:
New WHO STI Guidelines: Introduction and scaling up implementation, what does it take?

Background

Sexually transmitted infections (STIs) remain to be prevalent and continue to present a major burden of morbidity and mortality throughout the world, both directly, through their impact on quality of life, reproductive health, and child health, and indirectly, through their role in facilitating sexual transmission of HIV infection and their impact on national and individual economies.

Efforts to prevent and control STIs should be doubled in order to reduce STI burden and have an impact in HIV transmission and reproductive health. In order to scale up quality STI response and STI case management, effective guidelines based on evidence are essential. These publications provide basis for standardisation, training and supervision, continuous quality improvement as well as for programme management.

One of the WHO's core functions is to assess new evidence and innovations and translate them into concrete guidance for countries. These are intended to assist providers and recipients of health care and other stakeholders to make informed decisions.

WHO have just released several tools on surveillance and STI laboratory diagnosis. These includes the following:

- STI Laboratory: Laboratory Diagnosis of Sexually Transmitted Infections, including HIV
- STI Surveillance: Strategies and laboratory methods for strengthening surveillance of sexually transmitted infections
- Elimination of Congenital Syphilis: Methods for surveillance and monitoring of Congenital syphilis elimination with existing systems
- Cervical Cancer: Comprehensive Cervical Cancer Control: A guide to essential practice

A critical step in WHO publications, is the implementation of these publications as well as evaluation and monitoring. These needs to be made accessible and widely available.

WHO proposes to disseminate these publications and provide an orientation for IUSTI participants including programme managers, clinicians, scientists, laboratory technicians, epidemiologists.

Objectives

1. To present the key messages / contents of the new WHO STI publications
2. To elicit feedbacks on the new WHO STI publications that could inform the development of future or updated STI publications.
3. To identify priority actions to introduce the WHO STI publications in countries.

Methodology

Power Point presentation will be done to present the various STI guidelines. This will be followed by questions and answers to clarify some points in the presentation. A facilitated group discussion will follow to discuss recommendations to inform development of updated STI guidelines and identify key research agendas.

Name of the medicinal product: Aldara 5% cream. Qualitative and quantitative composition: Each sachet contains 12.5 mg of imiquimod in 250 mg cream (5 %). 100 mg of cream contains 5 mg of imiquimod. Excipients: methyl hydroxybenzoate (E218), propyl hydroxybenzoate (E216), cetyl alcohol, stearyl alcohol, isostearic acid, benzyl alcohol, white soft paraffin, polyethylene 60, sorbitan stearate, glycerol, xanthan gum, purified water. Therapeutic indications: Imiquimod cream is indicated for the topical treatment of: External genital and perianal warts (condylomata acuminata) in adults. Small superficial basal cell carcinomas (sBCCs) in adults. Clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AKs) on the face or scalp in immunocompetent adult patients when size or number of lesions limit the efficacy and/or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate. Contraindications: Hypersensitivity to the active substance or to any of the excipients. Pharmacodynamic properties: Pharmacotherapeutic group: Chemotherapeutics for topical use, antivirals: ATC Code: D06BB10. Marketing and authorisation holder: Meda AB. For information regarding special warnings and special precautions for use, interaction with other medicinal products and other forms of interaction and undesirable effects we may refer to the published Summary of Product Characteristics.
Programme

Chair persons:  M. Kamb (CDC), T. Wi (WHO)

WS.01  WHO Introduction of Guidelines: What does it take?
       N. Broutet, M. Kamb, Geneva, Switzerland

WS.02  Comprehensive Cervical Cancer
       N. Broutet Geneva, Switzerland

WS.03  Methods for surveillance and monitoring of elimination of mother-to-child transmission (eMTCT) of syphilis
       L. Newman, Geneva, Switzerland

WS.04  STI surveillance strategies
       L. Newman, Geneva, Switzerland

10:15 – 10:30  Open forum

10:30 – 10:45  Break

WS.05  Overview of the STI Laboratory Manual
        M. Unemo, Örebro, Sweden

WS.06  Choosing test for STIs
        E. Hook III, Birmingham, United States

WS.07  Laboratory Quality Management
        C. Ison, London, United Kingdom

WS.08  Gonococcal infections
        M. Unemo, Örebro, Sweden

WS.09  Chlamydial infections
        B. van der Pol, Indianapolis, United States

WS.10  Mycoplasma genitalium
        ???

12:30 - 13:30  Lunch

WS.11  Vaginal Infections
        C. Ison, London, United Kingdom

WS.12  Syphilis
        ???

WS.13  Chancroid, Donovanosis and LGV
        D. Lewis, Sandringham, South Africa

WS.14  Herpes simplex virus and HPV
        S. Garland, Parkville, Australia

WS.15  HIV testing
        ???

16:00  Facilitated discussion: John Papp (facilitator)
       - Overview of point of care (POC) tests for STIs

16:30  Gaps and research priorities in developing POC tests
       M. Lahra and C. Gaydos

16:30  Facilitated discussion: Jo-Anne Dillon (facilitator)
       - Recommendations for rolling out the guidelines

17:00  Conclusions and recommendations
       T. Wi and M. Kamb
Established and Emerging STD/HIV Interventions in Countries of the South and Countries of the North: The Program Science Perspective (organised by CDC and University of Manitoba Symposium)

Organisers: Sevgi O. Aral, Centers for Disease Control
James F. Blanchard, University of Manitoba

This one-day meeting will explore the planning, implementation and evaluation of STD/HIV intervention strategies in countries of the global North and South with diverse epidemiological, economic and health system contexts. Definition of intervention strategies will specify interventions or intervention packages; populations targeted and methods for determining target populations; frequency and intensity of intervention delivery and methods used to determine such frequency and intensity; duration of intervention delivery and monitoring and evaluation approaches. The interventions covered will include, but not be limited to, treatment as prevention, screening and treatment; test-and-treat; and pre-exposure prophylaxis. Intervention strategies will be discussed in relation to issues of resource allocation, effectiveness, efficiency, cost-effectiveness, marginal effectiveness, marginal costs and return on investments. Conceptual, theoretical (mathematical modeling) and empirical studies will be represented. The agenda for the meeting will include both invited and abstract driven presentations.

Programme

Chair: K. Holmes, Seattle, United States

PCS1.01 Welcome and Introductions
S. O. Aral, Atlanta, United States

PCS1.02 Established and Emerging STD/HIV Interventions: Opportunities and Challenges
J. Blanchard, Manitoba, Canada

PCS1.03 The changing nature and contribution of sex work to HIV transmission during the economic crisis in Zimbabwe.
J. Elmes, London, United Kingdom

PCS1.04 Implementation of the use of antiretrovirals for HIV pre-exposure prophylaxis in men who have sex with men: a work in progress
K. Mayer, Boston, United States

PCS1.05 Vaccination against human papillomavirus: Science, policy and program in the United States
L. Markowitz, Atlanta, United States

PCS1.06 Evaluation of Prevention of Mother to Child Transmission (PMTCT) HIV service delivery and uptake in a Demographic Surveillance Site (DSS) in northern rural Malawi
A. Price, London, United Kingdom

PCS1.07 Applying Program Science for strengthening the antenatal screening for HIV, syphilis and hepatitis B in Europe
C. Savolainen-Kopra, Helsinki, Finland

12:00 – 13:00 Lunch

Chair: W. Cates, Chapel Hill, United States

PCS1.08 Limits to the utility of randomized controlled trials and the need for systems science methods
J. Marazzo, Seattle, United States

PCS1.09 Understanding the impact and cost of scaling up targeted condom use HIV prevention interventions for female sex workers in India: Insights from mathematical modeling
J. Panovska-Griffiths, London, United Kingdom

PCS1.10 Modelling the impact and cost-effectiveness of treatment as prevention and pre-exposure prophylaxis amongst HIV serodiscordant couples in Nigeria
K. Mitchell, London, United Kingdom

PCS1.11 Maximizing the impact of federal STD prevention funds: Allocating resources across state and local areas
H. Chesson, Atlanta, United States

PCS1.12 Implementation of EPT: An analysis of comparative legal, government and healthcare systems of United States and Western Europe
R. Cramer, Atlanta, United States

PCS1.13 Program Science in remote Australia – using a continuous quality improvement program to reduce endemic rates in STI in remote Aboriginal communities in Australia
J. Ward, Sydney, Australia

PCS1.14 Wrap-up – Program Science: The Evolution
S. O. Aral, Atlanta, United States
13:00 – 15:15

Room: Geheime Ratstube
Joint symposium of the ÖGSTD (Austrian Society for STI and Dermatological Microbiology) and DSTIG (German Society for STI)

Chair: N. Brockmeyer, Bochum, Germany
C. Heller-Vitouch, Vienna, Austria

Programme

PCS2.01 Why is the genital mucosa not constantly infected by E. coli?
E. Tschachler, Vienna, Austria

PCS2.02 STI-Research: All eyes on Chlamydia trachomatis
D. Heuer, Berlin, Germany

PCS2.03 Gonorrhoea: A german guideline update
P. Spornraft-Ragaller, Dresden, Germany

PCS2.04 The heterogeneous clinical spectrum of primary syphilis
S. Lautenschlager, Zürich, Switzerland

PCS2.05 Neurosyphilis: a reemerging aspect of infection with Treponema pallidum
A. Geusau, Vienna, Austria

PCS2.06 Primary HIV infection – an ongoing challenge
A. Rieger, Vienna, Austria

PCS2.07 Black dermatology: cutaneous and mucocutaneous manifestation of STI/AIDS
Z. Abebe, Mekelle, Ethiopia

PCS2.08 STI-Counselling – For whom, how, and why? Recommendations of the DSTIG section for sexual health
E. Köhler, Frankfurt, Germany

15:30 – 17:00

Room: Geheime Ratstube
American Sexually Transmitted Diseases Association- Young Investigators Symposium
Research in Progress: Highlights from The American STD Association Developmental Awards Program

Chairs: B. Stoner, St. Louis, United States - President, American Sexually Transmitted Diseases Association
K. Rietmeijer, Denver, United States - President-Elect, American Sexually Transmitted Diseases Association

Synopsis: This symposium features contributions from recipients of the American Sexually Transmitted Disease Association (ASTDA) Development Awards Program. ASTDA started funding promising young investigators with these 2-year awards through a competitive process in 2008. To date, 10 investigators have been funded for a wide spectrum of STD-associated research projects, varying from laboratory basic science projects to behavioral interventions. In this symposium, recent recipients will discuss preliminary findings from their work. This session is intended to highlight the value of and need for promoting the entry of junior researchers into the field of STD research.

Programme

Introduction: B. Stoner and K. Rietmeijer

YI.1 Condom use & pleasure in a sample of young men who have sex with men
R. Arrington-Sanders, Baltimore, United States

YI.2 Teens, the Internet, and STD risk: findings and lessons learned from the Communication, Health and Teens (CH@T) study
E. Buih, Tampa, United States

YI.3 Sexually transmitted infections (STIs) vary among African American women who have sex with women based on exposure to male sexual partners
C. Muzny, Birmingham, United States

YI.4 Gonococcal genomics shows impact of recombination on obscuring phylogenetic signal and disseminating resistance loci
Y. Grad, Boston, United States

YI.5 Sexual risk factors amongst women who have sex with men and women: the Women in Indiana Sexual Health and Experience Study (WISHES)
V. R. Schick, Bloomington, United States

General Discussion & Adjourn, K. Rietmeijer and B. Stoner, Moderators
Innovative strategies for SYPHILIS and HIV testing in pregnant women

**Detect HIV and Syphilis in one device**
- Detection of antibodies to all isotypes (IgG, IgM, IgA) specific to HIV-1/2 and Treponema pallidum simultaneously

**Easy to use**
- Specimen: Whole blood / Serum / Plasma
- Assay time: 15−20 minutes
- Storage: 1-30°C
- Shelf life: 24 months

**Excellent performance**
- Sensitivity: HIV-100%
- Syphilis-99.0%
- Specificity: HIV-99.6%
- Syphilis-99.5%

Detect HIV and Syphilis in one device

**Easy to use**
- Specimen: Whole blood / Serum / Plasma
- Assay time: 15−20 minutes
- Storage: 1-30°C
- Shelf life: 24 months

**Excellent performance**
- Sensitivity: HIV-100%
- Syphilis-99.0%
- Specificity: HIV-99.6%
- Syphilis-99.5%

Free online access until July 31st!

... providing you with a leading international forum for investigating and treating sexually transmissible infections, HIV and AIDS.

The International Journal of STD & AIDS is now online on the award-winning SAGE Journals platform. Formerly published by the Royal Society of Medicine Press, this journal provides a unique international forum for investigating and treating sexually transmitted infections and HIV. Publishing original research and practical papers, the journal also contains in-depth review articles, short papers, case reports, audit reports and a lively correspondence column.

Publishing 12 times a year, this is the official journal of the British Association for Sexual Health & HIV (BASHH) and the International Union against Sexually Transmitted Infections (IUSTI).

All STI & AIDS World Congress delegates can access this journal for free at http://ijsa.sagepub.com until the end of July!
17:30 - 21:00
CONGRESS OPENING

17:30 – 19:30
Room: Festsaal
Opening Ceremony

Chairs: R. Patel, Southampton, United Kingdom
A. Stary, Vienna, Austria
T. Quinn, Baltimore, United States
C. Heller-Vitouch, Vienna, Austria

“Austrian Sound”
Åsa Elmgren (Sopran) and the Girls’ Choir

Angelika Stary
Welcome Address by the Chair of the STI & AIDS World Congress 2013, President of ISSTDR

Raj Patel
Welcome Address by the Co-Chair of the STI & AIDS World Congress 2013, President of IUSTI

Gerhard Aigner
Welcome Address by the Director General, Federal Ministry of Health

Erwin Tschachler
Welcome Address by the President of the Austrian Society of Dermatology and Venereology

Michael Waugh
Former IUSTI President of IUSTI: Memorial Address of Anton Luger †

“Viennese Chamber Music”
Maximilian Bratt (Violine), Pavel Kachnov (Piano)

Thomas Quinn
Welcome Address by the Chair of the International Scientific Committee of the STI & AIDS World Congress

Opening Keynote Lecture

KL.01 Ending the HIV/AIDS Pandemic: From Scientific Advances to Public Health Implementation
Anthony S. Fauci, Director of the National Institute of Allergy and Infectious Diseases, United States

“A Musical Bouquet: From Austria with Love”
Åsa Elmgren (Sopran), Maximilian Bratt (Violine), Pavel Kachnov (Piano)

19:30 - 21:00
Exhibition Area
Networking Event
## Plenary Session 01

**09:30 - 10:00**
D.01 Effective STD control programs are essential to prevent HIV transmission within populations.

## Coffee break / Exhibition / Poster viewing

**10:00 - 10:30**

## Poster viewing

**12:00 - 13:00**

**13:00 - 14:00**

**14:00 - 15:30**

**15:30 - 16:00**

**16:00 - 17:30**

**17:30 - 18:00**

**18:00 - 19:00**
<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:50 - 08:30</td>
<td>FESTSAAL</td>
<td>Hot Topics: Selected Poster Discussions 01</td>
</tr>
<tr>
<td>08:30 - 09:30</td>
<td></td>
<td>Plenary Session 01</td>
</tr>
<tr>
<td>09:30 - 10:00</td>
<td></td>
<td>D.01 Effective STD control programs are essential to prevent HIV transmission within populations</td>
</tr>
<tr>
<td>10:00 - 10:30</td>
<td></td>
<td>Coffee break / Exhibition / Poster viewing</td>
</tr>
</tbody>
</table>

**07:50 - 08:30**
*Room: Festsaal*

**Hot Topics: Selected Poster Discussions 01**

**Chairs:**
- R. Patel, Southampton, United Kingdom
- V. Varkonyi, Budapest, Hungary

**P3.007** Gonorrhea, Syphilis, Chlamydia and Trichomonas in children under thirteen years of age: national surveillance in the UK and Republic of Ireland
- K. E. Rogstad, G. Hughes, G. Debelle, J. Evans, R. Reading, Sheffield, United Kingdom

**P3.171** Sexually transmitted infections (STI) among youth with perinatal HIV infection
- P. Pathela, S. Braunstein, C. Shepard, J. Schillinger, New York, United States

**P3.169** Epidemiology of sexually transmitted infection among offenders following release from the justice system
- S. Wiehe, A. W. Burgess, M. C. Aalma, M. B. Rosenman, J. Fortenberry, Indianapolis, United States

**P3.023** Geographical clustering of repeat positive tests with Chlamydia trachomatis among young people (16-29 years); Identification of a hidden key Chlamydia population

**P3.063** Trends of neurosyphilis during a syphilis epidemic in British Columbia, Canada: it occurs early, not late?
- R. T. Lester, T. S. Hottes, S. Wong, M. Morshed, G. S. Ogilvie, M. Gilbert, Vancouver, Canada

**08:30 - 09:30**
*Room: Festsaal*

**Plenary Session 01**

**Chairs:**
- A. Stary, Vienna, Austria
- T. Quinn, Baltimore, United States

**PL01.1** Antimicrobial resistance in Neisseria gonorrhoeae and possible emergence of untreatable gonorrhoea: how, when and essential actions?
- M. Unemo, Orebro, Sweden

**PL01.2** HPV: Changing Screening Algorithms and Scaling Up Vaccination
- E. Franco, Montreal, Canada

**09:30 - 10:00**
*Room: Festsaal*

**Debate 01 “Effective STD Control Programmes are Essential to Prevent HIV Transmission within Populations”**

**Moderator:** M. Alary, Québec, Canada

**Pro:**
- M. Cohen, Chapell Hill, United States

**Contra:**
- R. Gray, Baltimore, United States

**10:00 - 10:30**
*Room: Festsaal*

Coffee break / Exhibition / Poster viewing
10:30 – 12:00
Room: Prinz Eugen Saal
Symposium 01 - Microbicides To Prevent HIV/STD 2013: An Update

Chairs: J. Marrazzo, Seattle, United States
        K. Bernstein, San Francisco, United States

S01.1  An update on topical microbicide development.
        I. McGowan, Pittsburgh, United States

S01.2  Vaginal delivery of microbicides: Multipurpose Technologies.
        H. Rees, Johannesburg, South Africa

S01.3  Making anal sex safe: current status of products for rectal use.
        R. Cranston, Pittsburgh, United States

S01.4  Biomarkers of safety in microbicide research.
        B. Herold, New York, United States

10:30 – 12:00
Room: Zeremoniensaal
Symposium 02 - Translating and Implementing the Results of Diagnostic Assay Evaluations: From the Research Laboratory to Patient Care

Chairs: M. Chernesky, Hamilton, Canada
        M. Gomberg, Moscow, Russia

S02.1  The Public Health need for Diagnostics and the Differing Pathways to Approval and Use Around the World.
        C. Deal, Bethesda, United States

S02.2  Overview of Rapid/Point of Care Diagnostic Tests for HIV and Current Challenges associated with HIV Testing.
        A. Singh, Edmonton, Canada

S02.3  Extra-genital CT/GC Testing by NAATS: Use in screening and prevalence of infection in MSM, issues in validation.
        J. Schachter, San Francisco, United States

S02.4  What are the most efficient ways to communicate research-derived information to clinical practice: the role of diagnostic and treatment guidelines, packet inserts, clinicians' perspective.
        J. White, London, United Kingdom

10:30 – 12:00
Room: Forum
Symposium 03 - Advancing Prevention of Sexually Transmitted Infections through Sexual Health Promotion: Opportunities and Lessons Learned (organised by CDC/WHO/ECDC)

Chairs: J. Douglas, Atlanta, United States (CDC)
        C. Garcia Moreno, Switzerland

S03.1  Sexual health: conceptual framework and recommendations for indicators.
        I. Toskin, Switzerland

S03.2  Sexual health promotion interventions: results of a systematic review
        M. Hogben, Atlanta, United States (CDC)

S03.3  Addressing gender-based violence to reduce risk of STI and HIV.
        C. Garcia Moreno, Switzerland

S03.4  Sexual health in the European Union: an inventory of data, programmes, initiatives, and policies
        M. van de Laar, Stockholm, Sweden (ECDC)

S03.5  Advancing sexual health in the US: from theory to action.
        J. Douglas, Atlanta, United States (CDC)
        Panel discussion among presenters: improving STI prevention by promotion of sexual health
10:30 – 12:00
Room: Rittersaal
Oral Session 01 - Microbial Virulence and Host Response

**Chairs:** S. Lukehart, Seattle, United States
G. Stingl, Vienna, Austria

**O01.1** Association of genetic variants with Chlamydia trachomatis reinfection
R. Kapil, J. Tang, C. G. Press, W. M. Geisler, Birmingham, United States

**O01.2** Innate immunity modulation by Trichomonas vaginalis galectin-binding glycolipid domains
R. N. Fichorova, H. S. Yamamoto, T. Fashemi, O. R. Buck, E. Foley, G. R. Hayes, S. Sato, B. N. Singh, Boston, United States

**O01.3** Regulatory T Cells in Peripheral Blood and Cerebrospinal Fluid of Syphilis Patients with and without Neurological Involvement: a Comprehensive and Comparative Study
K. Li, C. Wang, H. Lu, X. Gu, Z. Guan, P. Zhou, Shanghai, China

**O01.4** Blood transcriptional profiling of women with Chlamydia trachomatis identifies a pelvic inflammatory disease (PID) signature

**O01.5** Efficacy of RG1-VLP Vaccination against Genital and Cutaneous Human Papillomaviruses in Vitro and in Vivo
C. Schellenbacher, K. Kwak, D. Fink, S. Shafti-Keramat, B. Huber, C. Jindra, R. Roden, R. Kirnbauer, Vienna, Austria

**O01.6** Persistent SIV-seronegative macaque monkeys generate multi-cytokine anti-SIV mucosal immune responses following serial low-dose SIV mucosal challenge

10:30 – 12:00
Room: Gartensaal
Oral Session 02 - Antimicrobial therapy for genital tract infections

**Chairs:** M. Janier, Paris, France
A. Haçalı, Rabat, Morocco

**O02.1** A randomised, controlled study to assess the efficacy and safety of nifuratel vaginal tablets on bacterial vaginosis
W. Mendling, M. Casein, R. Palmeir, Wuppertal, Germany

**O02.2** Susceptibility of Bacterial Vaginosis (BV)-Associated Bacteria and Lactobacilli to Rifaximin, Metronidazole and Clindamycin
S. L. Hillier, L. Cosentino, M. Petrina, L. Rabe, Pittsburgh, United States

**O02.3** Treatment outcomes for persistent Mycoplasma genitalium-associated NGU: Evidence of moxifloxacin treatment failures
L. E. Manhart, C. M. Khosropour, C. W. Gillespie, M. S. Lowens, M. R. Golden, P. A. Totten, Seattle, United States

**O02.4** Persistent/recurrent chlamydial infection among STD clinic patients treated with CDC-recommended therapies
C. M. Khosropour, R. Duan, L. R. Mertsch, D. J. Feaster, M. R. Golden, Project Aware Study Team, Seattle, United States

**O02.5** A Phase II, dose ranging study to evaluate the efficacy and safety of single-dose oral solithromycin (CEM-101) for treatment of patients with uncomplicated urogenital gonorrhea
E. W. Hook III, B. D. Jamieson, D. Oldach, H. Harbison, A. Whittington, P. Fernandes, Birmingham, United States

**O02.6** Azithromycin versus doxycycline for the treatment of genital chlamydia infection - a meta-analysis of randomised controlled trials
J. Hocking, F. Kong, L. Vodstrcil, R. Guy, M. Chen, C. Fairley, C. Bradshaw, S. Tabrizi, Carlton, Australia
10:30 – 12:00
Room: Geheime Ratstube
Oral Session 03 - Neisseria gonorrhoeae Resistance: Superbug ante portas?

Chairs: P. Kohl, Berlin, Germany
D. Barlow, London, United Kingdom

O03.1 Risk factors for antimicrobial resistant Neisseria gonorrhoeae in Europe
M. J. Cole, G. Spiteri, K. Town, M. Unemo, S. Hoffmann, M. van de Laar, C. Ison, London, United Kingdom

O03.2 Antimicrobial resistance of Neisseria gonorrhoeae in the European Union: response to the threat of multidrug resistant gonorrhoea
G. Spiteri, M. Cole, M. Unemo, S. Hoffmann, C. Ison, M. van de Laar, Stockholm, Sweden

O03.3 Maximising the efficiency of gonorrhoea treatment by targeting the use of previous first line therapies to susceptible patients
K. Town, C. Obi, S. Chisholm, G. Hughes, C. A. Ison, London, United Kingdom

O03.4 Genomic epidemiology of Neisseria gonorrhoeae with reduced susceptibility to cefixime in the United States
Y. H. Grad, R. Kirkcaldy, D. Trees, J. Dordel, E. Goldstein, H. Weinstock, J. Parkhill, W. P. Hanage, S. Bentley, M. Lipsitch, Boston, United States

O03.5 Recent increases in gonorrhoea in Europe
G. Spiteri, K. Haar, O. Sfetcu, M. van de Laar, Stockholm, Sweden

O03.6 Using molecular typing to investigate N. gonorrhoeae strain turnover: A comparative study of GISP isolates collected from Baltimore and San Francisco
K. Espinosa, J. Gerrity, M. Pandori, V. Marsiglia, J. Hardick, M. Barnes, D. Hess, C. Gaydos, Baltimore, United States

10:30 – 12:00
Room: Trabantenstube
Oral Session 04 - Vaginal Infections and PID

Chairs: B. Stoner, St. Louis, United States
A. Robinson, London, United Kingdom

O04.1 The influence of hormonal contraception and pregnancy on the vaginal microbiome, sexually transmitted infections, and cytokine responses in a cohort of Rwandan sex workers
M. C. Verwijs, H. Borgdorff, F. W. N. M. Wit, F. H. Schuren, R. Lutter, R. Verhelst, M. J. M. Bonten, J. H. M. van de Wijgert, Amsterdam, Netherlands

O04.2 Hormonal contraception is associated with a reduced risk of bacterial vaginosis: A Systematic Review and Meta-Analysis

O04.3 Correlates of Incident Trichomonas vaginalis Infections Among African-American Adolescent Females
A. Swartzendruber, R. J. DiClemente, J. M. Sales, J. L. Brown, E. S. Rose, Atlanta, United States

O04.4 Seroprevalence of Herpes Simplex Virus Types 1 and 2 United States, 1999-2010
H. Bradley, L. E. Markowitz, T. Gibson, G. M. McQuillan, Atlanta, United States

O04.5 Comparison of the clinical and demographic characteristics of neonatal herpes infections caused by herpes simplex virus type 1 and type 2; findings from a population-based surveillance system, 2006-2012
J. A. Schillinger, K. Washburn, E. Klingler, S. Blank, P. Pathela, Atlanta, United States

O04.6 Mycoplasma Genitalium - Is it a Pathogen in Acute Pelvic Inflammatory Disease (PID)?
H. C. Wiesendfeld, S. L. Hillier, L. Meyn, G. Trucco, A. Amortegui, I. S. Macio, L. Rabe, L. Cosentino, T. Darville, Pittsburgh, United States

12:00 – 14:00
Lunch Satellite Symposia

SEE PROGRAMME PAGE XX
14:00 – 15:30
Room: Prinz Eugen Saal
Symposium 04 - Scaling up of HIV treatment programs among the most at-risk populations in low- and middle-income countries

Chairs: M. Alary, Québec, Canada
N. Nagot, Montpellier, France

S04.1 Scaling up of HIV treatment programs among the most at-risk populations in low- and middle-income countries - introduction
M. Alary, Québec, Canada

S04.2 Modelling the impact of early anti-retroviral treatment amongst people who inject drugs in a high prevalence setting
P. Vickerman, London, United Kingdom
Experience with ART use among HIV-infected FSW

S04.3 Antiretroviral therapy among female sex workers in Burkina Faso: current situation
I. Konate, Bobo-Dioulasso, Burkina

S04.4 ART among FSW in South Africa.
F. Venter, Johannesburg, South Africa.

S04.5 ART among FSW in India.
S. Mishra, London, UK

S04.6 Examining the population-level impact of scaling-up ART for FSWs across epidemic context.
M-C. Boily, London, United Kingdom

General Discussion

14:00 – 15:30
Room: Zeremoniensaal
Symposium 05 - Fostering an Integrated Approach to the Control of Antimicrobial Resistance in Neisseria gonorrhoeae (organised by WHO)

Chairs: G. Bolan, Atlanta, United States
M. Lahra, Randwick, Australia

S05.1 Antimicrobial resistance in N. gonorrhoeae: Update of the situation.
T.Wi, Geneva, Switzerland

S05.2 Challenges and Opportunities: Potentials in Research on AMR Gonococci
C. Deal, Bethesda, United States

S05.3 Genetic resistance determinants for extended-spectrum cephalosporins - possibilities for genetic resistance testing?
M. Unemo, Orebro, Sweden

S05.4 Integrating antimicrobial susceptibility monitoring in N. gonorrhoeae to broader AMR agenda.
M. Ghidinelli, Washington, United States

Round table discussion: Implementation of the WHO global action plan to control the spread and impact of AMR in N.G.

Panellists:
M. Bala, New Delhi, India (South East Asia Region)
J-A. Dillon, Saskatoon, Canada (Region of the Americas)
M. Lahra, Randwick, Australia (Western Pacific Region)
M. Unemo, Orebro, Sweden (European Region)
S. Kidd, Atlanta, United States (United States)
<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Session Title</th>
<th>Authors</th>
</tr>
</thead>
</table>
| 14:00 – 15:30 | Forum              | Oral Session 05 - Molecular Analysis of STI Pathogens and their Environments | Chairs: L. Stanberry, New York, United States  
S. Hillier, Pittsburgh, United States  
O05.1 High grade anal intraepithelial neoplasia: one virus, one lesion  
O05.2 Measuring syphilis: Quantitative PCR can be used to monitor treatment response  
C. Tipple, L. Hodson, R. Jones, M. Raymond, N. Nwokolo, M. McClure, G. Taylor, London, United Kingdom  
O05.3 More than meets the eye: A molecular phylogenetic analysis reveals importance of novel bacteria in bacterial vaginosis (BV)  
S. Srinivasan, M. T. Morgan, C. Liu, F. A. Matsen, N. G. Hoffman, T. L. Fiedler, K. J. Agnew, J. M. Marrazzo, D. N. Fredricks, Seattle, United States  
O05.4 Association between Chlamydia trachomatis genital infection and the vaginal microbiome  
O05.5 A longitudinal study of the vaginal microbiota and HPV detection  
R. M. Brotman, M. D. Shardell, P. Gajer, J. K. Tracy, J. M. Zenilman, J. Ravel, P. E. Gravitt, Baltimore, United States  
O05.6 Endometrial Gardnerella vaginalis and Atopobium vaginae are associated with histologic endometritis among women with clinically diagnosed pelvic inflammatory disease (PID)  
S. L. Hillier, L. K. Rabe, L. Meyn, I. Macio, G. Trucco, A. Amortegui, T. Darville, H. C. Wiesenfeld, Pittsburgh, United States |
| 14:00 – 15:30 | Rittersaal         | Oral Session 06 - Clinical Issues and Potential Solutions                     | Chairs: M. Cusinsi, Milan, Italy  
M. Vall Mayans, Barcelona, Spain  
O06.1 Evaluation of 5 different tests for Trichomonas vaginalis (TV) infection and cost effective planning for clinical implementation  
B. Nathan, J. Appiah, D. Heron, P. Saunders, R. Brum, S. Alexander, P. Baraetser, C. Ison, London, United Kingdom  
O06.2 A pilot randomized controlled trial of high-dose vitamin D supplementation to prevent recurrence of bacterial vaginosis  
A. Norris Turner, P. Carr Reese, J. Anderson, K. S. Fields, M. Ervin, M. Klebanoff, R. Jackson, Columbus, United States  
O06.3 Macrolide resistance of Mycoplasma genitalium in France directly detected in clinical specimens by real-time PCR and melting curve analysis  
A. Touati, O. Peuchant, J. Skov-Jensen, C. Bébéar, S. Pereyre, Bordeaux, France  
O06.4 Using SMS text reminders to reduce ‘did not attend’ (DNA) rates in sexual health and HIV appointment clinics  
G. Brook, T. Farmer, S. Murphy, J. McSorley, London, United Kingdom  
O06.5 An exploratory evaluation of universal opt-out chlamydia testing during clinical encounters for young women in the United States  
K. Owusu-Edusei, K. W. Hoover, G. D. Hart-Cooper, T. L. Gift, Atlanta, United States  
O06.6 A randomised, double-blind, controlled study to assess the efficacy and safety of nifuratel in the treatment of trichomoniasis  
W. Mendling, M. Caserini, R. Palmieri, Wuppertal, Germany |
14:00 – 15:30

**Room: Gartensaal**

**Oral Session 07 - Sexually Transmitted Infections: Social and Behavioral Determinants and Consequences**

**Chairs:**
- **H. Ward,** London, United Kingdom
- **J. Blanchard,** Winnipeg, Canada

**007.1** Sexual relationship importance and condom use among men attending STD clinics in two southern cities in the United States


**007.2** The changing relationship between migration and HIV over the life course of affected households in north India

**T. Rai,** H. S. Lambert, P. Fiot, K. S. Agarwal, H. Ward, London, United Kingdom

**007.3** A psychological experiment to examine the global impact of stigma on individuals diagnosed with type 1 herpes simplex virus (HSV-1)

**J. Whale,** E. Clarke, N. Patel, C. Graham, R. Ingham, R. Patel, Southampton, United Kingdom

**007.4** The price of sex: insights into the determinants of the price of commercial sex among female sex workers in rural Zimbabwe


**007.5** Unprotected sex among high-risk partners: associations between relational characteristics of last sexual partner and unprotected anal intercourse (UAI) among men who have sex with men (MSM) and transgender women (TWG) in Lima, Peru

**M. C. Cambou,** A. Perez-Brumer, E. R. Segura, J. Salvatierra, J. Peinado, J. R. Lama, J. Sanchez, J. L. Clark, Los Angeles, United States

**007.6** Age related differences in contraceptive prevalence and preference among harder-to-reach women on antiretroviral therapy (ART) living with HIV in British Columbia (BC), Canada

**S. Patterson,** K. Salters, W. Zhang, Y. Chen, B. Hogg, G. Ogilvie, A. Kaida, Burnaby, Canada

---

14:00 – 15:30

**Room: Geheime Ratstube**

**Oral Session 08 - Get those partners treated!**

**Chairs:**
- **J. Zenilman,** Baltimore, United States
- **F. Judson,** Denver, United States

**008.1** Assessing the added value of internet partner services for syphilis and HIV

**K. T. Bernstein,** R. Kohn, W. Wolf, F. Strona, C. Fann, S. Philip, San Francisco, United States

**008.2** Use and effectiveness of an online partner notification tool for STI, called Suggest-A-Test

**H. M. Götz,** M. S. van Rooijen, P. Viens, E. Op de Coul, M. Hamers, T. Heijman, F. van den Heuvel, R. Koekenbier, P. van Leeuwen, H. Voeten, Rotterdam, Netherlands

**008.3** Barriers to bacterial STI screening of HIV+ men who have sex with men (MSM) in HIV Care Primary Settings

**L. A. Barbee,** S. Dhanireddy, S. Tat, A. Radford, J. M. Marracco, Seattle, United States

**008.4** Online access to home STI specimen collection and e-prescriptions linked to public health - is a comparative effectiveness trial feasible?

**F. Spielberg,** V. Levy, I. Kapur, S. Lensing, N. Acevedo, L. Venkatasubramanian, C. Leivermann, S. Philip, N. PADIAN, C. Gaydos, Washington, United States

**008.5** Should all pregnant women be screened for chlamydia infection as recommended by CDC, or only those younger than 25 years as recommended by USPSTF?

**G. Tso,** K. Hoover, Atlanta, United States

**008.6** Do you have an STI? Findings from a dedicated men’s sexual health clinic in Alexandra township, South Africa

**D. A. Lewis,** C. Ricketts, A. Vezi, V. Maseko, Sandringham, South Africa

---

14:00 – 15:30

**Room: Trabantenstube**

**Oral Session 09 - Programme implementation and scaling up**

**Chairs:**
- **C. Ritmeijer,** Denver, United States
- **A. Schwartz Benzaken,** Manaus, Brazil

**009.1** Voices of HIV infected Children and their Families

**B. Panda,** K. Shaw, Kolkata, India

**009.2** Financing free and universal access to antiretroviral drugs in the long-run: ART cost evolution in Brazil

**C. Meiners-Chabin,** Brasilia, Brazil

**009.3** A successful model in reaching out mobile population to control the spread of STI/HIV/AIDS: Experience from Link Worker Scheme implemented in 200 villages mostly inhibited by mobile population in West Bengal, India

**B. Panda,** D. Ghosh, A. Ishlam, R. Kundu, M. Mahato, Kolkata, India

**009.4** Mobilization for HIV, Syphilis and Hepatitis B and C testing during Brazil’s carnival

**A. Bolzan,** E. Santos, D. Serofim, E. Ayer, A. Neto, M. Chaves, G. Araujo, J. Carneiro, Brasilia, Brazil

**009.5** Optimizing care efficiency at the STI clinic: using Chlamydia home collection kits

**R. Koekenbier,** A. Hendriks, M. van Veen, P. van Leeuwen, Amsterdam, Netherlands

**009.6** CD4 below 500: increase of ART patients and the financial impact in Brazil

**F. Viegas Neves da Silva,** A. Guimarães, R. Hallal, D. Greco, Brasilia, Brazil

---

15:30 – 16:00

Coffee break / Exhibition / Poster viewing
WHAT YOU DO TODAY CAN IMPACT THEIR TOMORROW

Before prescribing ISENTRESS® please read the Prescribing Information.

For the summary of product characteristic please see page

Merck Sharp & Dohme Ges.m.b.H. Europlaza Gebäude G, Am Europlatz 2, 1120 Wien © Registered Trademark

© Urheberrechtlich geschützt für Merck Sharp & Dohme Corp., ein Unternehmen von Merck & Co., Inc., Whitehouse Station, NJ, USA.
16:00 - 17:30
Room: Festsaal
Plenary Session 02

Chairs: K. Holmes, Seattle, United States
       B. Donovan, Sydney, Australia

PL02.1 The Dynamic Evolution of Sexual Behavior as it Impacts STD Spread
       S. Aral, Atlanta, United States

PL02.2 Maximizing Impact and Return on Investments in STD/HIV Prevention Programmes
       D. Wilson, Washington, United States

PL02.3 HIV Transmission Dynamics: Can We Translate Knowledge into Action
       T. Quinn, Baltimore, United States

17:30 - 18:00
Room: Festsaal
Debate 02 “Social and behavioral interventions are no longer a priority in HIV prevention programmes?”

Moderator: H. Ward, London, United Kingdom
Pro: T. Bärnighausen, Boston, United States
Contra: J. Auerbach, San Francisco, United States

18:00 – 19:00
Poster Area: Ground Floor
Poster viewing with authors

Tracks:
P03 - Epidemiology and Prevention Sciences Track P3.001 - P3.449
P04 - Social and Behavioural Sciences Track P4.001 - P4.152

18:00 – 19:00
Satellite Symposia
SEE PROGRAMME PAGE XX

ROOM | PRINZ EUGEN SAAL | FORUM
--- | --- | ---
18:00 - 19:00 | SAT04 - Bacterial STIs in Europe
               Sponsored by Astellas Pharma Europe B.V | SAT05 - Molecular Diagnostics: A Syndromic Approach to STI & Vaginitis Testing. Where should Trichomonas vaginalis be included? Sponsored by BD Diagnostics
SCIENTIFIC PROGRAMME

TUESDAY, JULY 16, 2013
### TUESDAY, JULY 16, 2013

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:50 - 08:30</td>
<td>HotTopics: Selected Poster Discussions 02</td>
</tr>
<tr>
<td>08:30 - 10:00</td>
<td>Plenary Session 03: Anton Luger Memorial</td>
</tr>
<tr>
<td>10:00 - 10:30</td>
<td>Coffee break / Exhibition / Poster viewing</td>
</tr>
<tr>
<td>10:30 - 12:00</td>
<td>Plenary Session 03: Anton Luger Memorial</td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td>Poster viewing Exhibition Lunch Satellite Symposia</td>
</tr>
<tr>
<td>13:00 - 14:00</td>
<td>Plenary Session 04</td>
</tr>
<tr>
<td>14:00 - 15:30</td>
<td>Plenary Session 04</td>
</tr>
<tr>
<td>15:30 - 16:00</td>
<td>Plenary Session 04</td>
</tr>
<tr>
<td>16:00 - 17:30</td>
<td>Plenary Session 04</td>
</tr>
<tr>
<td>17:30 - 18:00</td>
<td>Plenary Session 04</td>
</tr>
<tr>
<td>18:00 - 19:00</td>
<td>Plenary Session 04</td>
</tr>
<tr>
<td>19:30</td>
<td>Congress Evening</td>
</tr>
</tbody>
</table>

**Rooms:**
- FESTSAAL
- PRINZ EUGEN SAAL
- ZEREMONIENSAAL
- FORUM
- RITTERSAAL
- GARTENSAAL
- GEHEIME RATSTUBE
- TRABANTENSTUBE
07:50 - 08:30
Room: Festsaal
Hot Topics: Selected Poster Discussions 02

Chairs: A. Geusau, Vienna, Austria
L. Foley, Southampton, United Kingdom

P3.449 The promise of estriol cream for prevention of vaginal infection in premenopausal women

P3.184 Sexually transmitted infections and pregnancy outcomes, Florida 2008-2010
K. Schmitt, D. R. Thompson, Tallahassee, United States

P3.016 Prevalence and correlates of rectal-only Chlamydia infection at two Canadian STI clinics
J. Gratrix, J. Bergman, C. Egan, A. E. Singh, S. Drews, R. R. Read, Calgary, Canada

P3.066 Rates and trends of pelvic inflammatory disease and ectopic pregnancy in England up to 2011: what can these data tell us about chlamydia epidemiology and control?
S. C. Woodhall, S. Wetten, J. Ross, T. Williams, G. Hughes, K. Soldan, London, United Kingdom

P3.019 Is concurrency, number of partners or duration of partnership the most important factor associated with chlamydia in young Australian adults?
A. Yeung, M. Temple-Smith, A. Bingham, C. Fairley, M. Low, R. Guy, N. Low, B. Donovan, J. Kaldor, J. Hocking, Melbourne, Australia

08:30 - 10:00
Room: Festsaal
Plenary Session 03: Anton Luger Memorial

Chairs: R. Patel, Southampton, United Kingdom
E. Tschachler, Vienna, Austria

PL03.1 STIs – 2013: Resurgence of Early Syphilis, Persistence of High STI Morbidity and Mortality, and Emergence of Antimicrobial Resistant STIs: Implications and Potential Responses.
K. Holmes, Seattle, United States

PL03.2 Control of syphilis in the world’s most populous country: opportunities and challenges
X-S. Chen, Nanjing, China

PL03.3 Syphilis: From Pathogenesis to Control
S. Lukehart, Seattle, United States

10:00 - 10:30
Coffee break / Exhibition / Poster viewing
### Symposium 06 - How Does Your Partner Know?

**Chairs:** M. Golden, Seattle, United States  
C. Fairley, Melbourne, Australia

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>S06.1</td>
<td>Treating contacts to gonorrhea and chlamydia without a clinic visit; the efficacy and effectiveness of different models.</td>
<td>J. Schillinger, New York, United States</td>
</tr>
<tr>
<td>S06.2</td>
<td>Using social media for partners services in adolescents.</td>
<td>K. Rietmeijer, Denver, United States</td>
</tr>
<tr>
<td>S06.3</td>
<td>MSM Partner Services: What works?</td>
<td>M. Steben, Montréal, Canada</td>
</tr>
<tr>
<td>S06.4</td>
<td>New directions in HIV partner services: an evolving model of global, integrated field services.</td>
<td>M. Golden, Seattle, United States</td>
</tr>
</tbody>
</table>

### Symposium 07 - Bacterial Virulence and Host Response

**Chairs:** D. Lewis, Johannesburg, South Africa  
C. Ison, London, United Kingdom

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>S07.1</td>
<td>Insights into maternal gonorrhea: human primary cervical and amniochorionic epithelial cell responses to <em>Neisseria gonorrhoeae</em> infection.</td>
<td>J. Edwards, Columbus, United States</td>
</tr>
<tr>
<td>S07.2</td>
<td>The extrusion paradigm of Chlamydia pathogenesis.</td>
<td>K. Hybiske, Berkeley, United States</td>
</tr>
<tr>
<td>S07.3</td>
<td>Survival Strategies of Haemophilus ducreyi: Role of Transporters.</td>
<td>M. Bauer, Indianapolis, United States</td>
</tr>
<tr>
<td>S07.4</td>
<td>Identification of determinants triggering antigenic variation in <em>Mycoplasma genitalium</em>.</td>
<td>R. Burgos Castellanos, Seattle, United States</td>
</tr>
<tr>
<td>S07.5</td>
<td>Understanding dissemination of Treponema pallidum within the host; is there hope for a syphilis vaccine?</td>
<td>C. Cameron, Victoria, Canada</td>
</tr>
</tbody>
</table>

### Symposium 08 - STI/HIV Treatment Guidelines: Important Areas of Clinical Uncertainty

**Chairs:** K. Radcliffe, Birmingham, United Kingdom  
K. Workowski, Atlanta, United States

**Presentations of Guideline Issues and Panel discussion, K. Workowski, Atlanta, United States**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>S08.1</td>
<td>Treatment of gonorrhea in an era of emerging cephalosporin resistance and results of a randomized trial of new potential treatment options</td>
<td>B. Kirkcaldy, Atlanta, United States</td>
</tr>
<tr>
<td>S08.2</td>
<td>Is azithromycin the best treatment for chlamydia?</td>
<td>K. Radcliffe, Birmingham, United Kingdom</td>
</tr>
<tr>
<td>S08.3</td>
<td><em>Mycoplasma genitalium</em> and <em>Chlamydia trachomatis</em> in laparoscopically diagnosed pelvic inflammatory disease.</td>
<td>C. Bjartling, Malmo, Sweden</td>
</tr>
<tr>
<td>S08.4</td>
<td><em>Mycoplasma genitalium</em>: implications for disease, treatment and the public health.</td>
<td>J. Jensen, Copenhagen, Denmark</td>
</tr>
</tbody>
</table>
10:30 – 12:00
Room: Rittersaal
Oral Session 10 - HPV: genital tract malignancy and vaccination

Chairs: J. Paavonen, Helsinki, Finland
J. Sherrard, Oxford, United Kingdom

**O10.1** Age Specific Round 1 Results of a Cervical Cancer Screening Trial: HPV FOCAL

**O10.2** A community-randomized phase IV human papillomavirus (HPV) vaccination trial of vaccination strategy
J. Paavonen, Helsinki, Finland

**O10.3** Predictors of women’s intentions to receive cervical cancer screening with primary HPV testing
G. Ogilvie, L. Smith, D. van Niekerk, F. Khursheed, S. Greene, S. Hobbs, A. Calman, E. Franco, Vancouver, Canada

**O10.4** Efficacy and safety of intravaginal (IL) injection of Mycobacterium w vaccine vs. Imiquimod cream in the treatment of anogenital warts: A double blind randomized trial
S. Gupta, L. Dar, P. Kumar, V. Sharma, K. Verma, S. N. Dwivedi, New Delhi, India

**O10.5** Human papillomavirus (HPV) genotypes associated with persistent HSIL isolated by laser capture microdissection
A. M. Cornall, J. Roberts, S. M. Garland, R. J. Hillman, M. Poyten, F. Jin, A. E. Grulich, S. N. Tabrizi, Parkville, Australia

**O10.6** A potent combination microbicide gel inhibits SHIV-RT, HSV-2 and HPV infections in vivo

10:30 – 12:00
Room: Gartensaal
Oral Session 11 - HIV Prevention and lessons learned from trials of HIV Pre-exposure Prophylaxis

Chairs: M. Cohen, Chapel Hill, United States
J. Hutterer, Vienna, Austria

**O11.1** Herpes simplex virus (HSV) infection in the VOICE (MTN 003) Study: pre-exposure prophylaxis (PrEP) for HIV with daily use of oral tenofovir, oral tenofovir-emtricitabine, or vaginal tenofovir gel
J. Marrazzo, L. Rabe, C. Kelly, T. Livant, M. Chirenje, B. Richardson, C. Deal, J. Piper, S. Hillier, Seattle, United States

**O11.2** Sexual behavior of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: Post-unblinding analysis of the Partners PrEP Study

**O11.3** Using HCV incidence trends to disentangle the likely impact of HIV anti-retroviral treatment on decreasing HIV incidence amongst injecting drug users: a modelling analysis
C. Chiyaka, N. Martin, M. Hickman, P. Vickerman, London, United Kingdom

**O11.4** Population-based HIV Incidence among men diagnosed with infectious syphilis, 2000-2011
P. Pathela, S. Braunstein, C. Shepard, J. Schillinger, Queens, United States

**O11.5** Risks for sexually transmitted infections (STIs), HIV, and pregnancy among women working in entertainment establishments in Cambodia

**O11.6** Migration and HIV Risk in Rakai Youth, 2000-2010
10:30 – 12:00

**Room: Geheime Ratstube**

**Oral Session 12 - Social Determinants and Structural Interventions**

**Chairs:**
- G. Hart, London, United Kingdom
- N. Brockmeyer, Bochum, Germany

**O12.1** Using social determinants to predict Neisseria gonorrhoeae infection risk at the census tract-level: findings from the STD Surveillance Network (SSuN), United States

**M. Stenger,** M. Samuel, H. Weinstock, Atlanta, United States

**O12.2** Church attendance in men who have sex with men diagnosed with HIV is associated with later presentation

**N. J. Van Wagoner,** M. Mugavero, A. Westfall, J. Hollimon, L. Slater, G. Burkholder, J. Raper, E. W. Hook, Birmingham, United States

**O12.3** Evaluation of a community-based HIV preventive intervention for female sex workers in rural areas of Karnataka state, South India

**R. G. Washington,** A. Narth, P. Jawalkar, S. Isac, S. Moses, Bangalore, India

**O12.4** Design and feasibility of Yo Puedo, a combined conditional cash transfer and life skills sexual health intervention for adolescents in San Francisco, California: results of a randomized study


**O12.5** Why is Australia giving free HPV vaccination to boys?

**B. Donovan,** Sydney, Australia

**O12.6** Understanding experiences and impact of domestic violence and abuse in gay and bisexual men attending a sexual health service in the UK

**L. J. Bacchus,** A. Buller, C. Sethi, J. White, London, United Kingdom

---

10:30 – 12:00

**Room: Trabantenstube**

**Oral Session 13 - Epidemic appraisal and strategic planning**

**Chairs:**
- G. Garnett, London, United Kingdom
- X-S. Chen, Nanjing, China

**O13.1** The use of rapid epidemic appraisals for planning and scaling up focused HIV prevention programs for female sex workers in Nigeria


**O13.2** Can the UNAIDS Modes of Transmission Model be improved? A comparison of the original and revised model projections using data from Nigeria.


**O13.3** Estimating the epidemiological impact of antiretroviral treatment on heterosexual HIV epidemics in south India: a modeling study

**S. Mishra,** E. Mountain, M. Pickles, P. Vickerman, S. Shastri, R. Washington, M. Becker, M. Alary, M. Boily, the Strategic Epi-ART in India Modeling Team, London, United Kingdom

**O13.4** An ethnographic mapping study of “money boys” and the male sex trade industry in Chengdu, South West China

**B. Yu,** X. Wang, J. Zhang, X. Ma, S. Khan, J. Blanchard, R. Lorway, Winnipeg, Canada

**O13.5** The HIV Modes of Transmission Model: a systematic review of its findings and adherence to guidelines

**Z. Shubber,** S. Mishra, J. F. Vesga, M. C. Boily, London, United Kingdom

**O13.6** Focusing the delivery of the English National Chlamydia Screening Programme: exploring opportunities to expand testing within local services


---

12:00 - 14:00

**Lunch Satellite Symposia**

SEE PROGRAMME PAGE XX
<table>
<thead>
<tr>
<th>ROOM</th>
<th>PRINZ EUGEN SAAL</th>
<th>ZEREMONIENSAAL</th>
<th>FORUM</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 - 15:30</td>
<td>S.09 Molecular Mechanisms of Antimicrobial Resistance</td>
<td>S.10 HIV Treatment as Prevention</td>
<td>S.11 National Trends in Sexual Behavior: USA, UK and Switzerland</td>
</tr>
</tbody>
</table>

14:00 – 15:30

**Room: Prinz Eugen Saal**

**Symposium 09 - Molecular Mechanisms of Antimicrobial Resistance**

**Chairs:**
- J-A. Dillon, Saskatoon, Canada
- J. Jensen, Copenhagen, Denmark

**S09.1** Molecular detection of antimicrobial resistance in STI pathogens.
- **D. Whitley**, St. Lucia, Australia

**S09.2** Neisseria gonorrhoeae.
- **C. Isom**, London, United Kingdom

**S09.3** Herpes simplex virus.
- **F. Morfin**, Lyon, France

**S09.4** Mycoplasma genitalium.
- **J. Jensen**, Copenhagen, Denmark

14:00 – 15:30

**Room: Zeremoniensaal**

**Symposium 10 - HIV Treatment as Prevention**

**Chairs:**
- P. Garcia, Lima, Peru
- J. Ross, Birmingham, United Kingdom

**S10.1** Predicting the Social and Behavioural Consequences.
- **M. Hogben**, Atlanta, United States

**S10.2** Determining uptake, adherence & patterns of ART use as prevention.
- **M. Cohen**, Chapel Hill, United States

**S10.3** Modeling the effect of TAP on the HIV/AIDS Epidemic.
- **G. Garnett**, London, United Kingdom

**S10.4** Discussant.
- **J. Ross**, Birmingham, United Kingdom

14:00 – 15:30

**Room: Forum**

**Symposium 11 - National Trends in Sexual Behaviour: USA, UK and Switzerland**

**Chairs:**
- S. Aral, Atlanta, United States
- D. Freedman, Dublin, Ireland

**S11.1** Sexual behaviour in Britain in the new millennium: A new era?
- **C. Mercer**, London, United Kingdom

**S11.2** Sex in the United States in the New Millennium: Temporal Trends among Men and Women Aged 15-44 Years.
- **J. Leichliter**, Atlanta, United States

**S11.3** Switzerland: national trends in sexual behaviour in the context of HIV/STI behavioural surveillance 1987-2012.
- **F. Dubois-Arber**, Lausanne, Switzerland

**S11.4** Discussant.
- **D. Freedmann**, Dublin, Ireland
14:00 – 15:30

**Room:** Rittersaal

**Oral Session 14 - Clinical Syndromes**

**Chairs:** A. Poder, Tartu, Estonia  
J. Pace, Malta

**O14.1** Bacterial vaginosis-associated bacteria (BVAB) and non-gonococcal urethritis (NGU)  
L. E. Manhart, C. M. Khasroopur, C. Liu, C. W. Gillespie, K. Depner, T. Fiedler, J. M. Marrazzo, D. N. Fredricks, Seattle, United States

**O14.2** Predictors and pathogens among 4,126 cases of acute non-gonococcal urethritis  
V. S. Rane, C. K. Fairley, A. Weerakoon, M. Y. Chen, T. R. Read, C. S. Bradshaw, Carlton, Australia

**O14.3** Long-term efficacy of human papillomavirus vaccination against cervical cancer  
J. Paavonen, Helsinki, Finland

**O14.4** Microbiologic etiology of proctitis diagnosed in an urban STD clinic  

**O14.5** Occurrence of vaccine and non-vaccine human papillomavirus (HPV) types in the female population before and after the HPV vaccination  
J. Paavonen, Helsinki, Finland

**O14.6** Aetiology of Infectious Proctitis Differs by HIV status  
M. Bissessor, C. K. Fairley, T. R. Read, I. M. Denham, C. S. Bradshaw, M. Y. Chen, Melbourne, Australia

---

**Know for sure!**

PapilloCheck® and PapilloCheck® high-risk HPV-Genotyping:  
The Clear Edge in Early Detection of Cervical Cancer.

- Identification of human pathogenic HPV types  
- Differentiation between single and multiple infections  
- Classification according to the risk potential  
- Integrated quality control system  
- High clinical sensitivity and specificity  
- CE-certified in vitro diagnostics

<table>
<thead>
<tr>
<th>PapilloCheck® low-risk types</th>
<th>PapilloCheck® high-risk types</th>
</tr>
</thead>
<tbody>
<tr>
<td>6, 11</td>
<td>16, 18, 31</td>
</tr>
<tr>
<td>40, 42</td>
<td>33, 35, 39</td>
</tr>
<tr>
<td>43, 44</td>
<td>45, 51, 52</td>
</tr>
<tr>
<td>53, 56, 58</td>
<td>59, 66, 68</td>
</tr>
<tr>
<td>70</td>
<td>73, 82</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PapilloCheck® high-risk types</th>
</tr>
</thead>
<tbody>
<tr>
<td>16, 18</td>
</tr>
<tr>
<td>31, 33</td>
</tr>
<tr>
<td>35, 39</td>
</tr>
<tr>
<td>45, 51</td>
</tr>
<tr>
<td>52, 56</td>
</tr>
<tr>
<td>58, 59</td>
</tr>
<tr>
<td>68</td>
</tr>
</tbody>
</table>

PapilloCheck® and PapilloCheck® high-risk are part of the vCheck® product line from Greiner Bio-One GmbH.
14:00 – 15:30
**Room: Gartensaal**
**Oral Session 15 - For Lab Rats and other Mice and Men**

**Chairs:** C. Gaydos, Baltimore, United States  
D. Patton, Washington, United States

**O15.1** Sub-optimal CD4 T-cell recovery in HIV-1 subtype C patients on antiretroviral therapy: A search for predictive biomarkers and baseline characteristics  

**O15.2** Comparison of the Roche cobas 4800 CTNG test with microbial culture for detecting Neisseria gonorrhoeae in genital and non-genital specimens in New Zealand  
*A. Miller, C. Bromhead, M. Jones, D. Whiley, A. Upton, Wellington, New Zealand*

**O15.3** Evaluation of an immunochromatographic point-of-care test for the simultaneous detection of non treponemal and treponemal antibodies in patients with syphilis  
*R. Castro, A. Lopes, Lisboa, Portugal*

**O15.4** Field performance of the Alere Determine HIV Combo assay in a large Australian multi-centre study in a sexual health clinic setting  

**O15.5** Performance characteristics of SD Bio line rapid HIV-Syphilis Duo test kit for simultaneous detection of HIV and Syphilis infections  
*R. O. Onondo, J. B. Odoyo, E. A. Bukusi, Nairobi, Kenya*

**O15.6** Molecular surveillance of Neisseria gonorrhoeae penicillin resistance: informing empiric prescribing policy in Western Australia  
*D. J. Speers, N. Goire, D. Mak, R. Fisk, Perth, Australia*

---

14:00 – 15:30
**Room: Geheime Ratstube**
**Oral Session 16 - STI-Potpourri: Chlamydia, HPV and Special populations**

**Chairs:** S. Lautenschlager, Zürich, Switzerland  
M. Potocnik, Ljubljana, Slovenia

**O16.1** The behavioural impact of chlamydia testing and attitudes towards testing among young adults in England  
*T. Hartney, P. Baratise, A. Nardone, London, United Kingdom*

**O16.2** Strain typing to resolve repeated Chlamydia trachomatis infections in young heterosexual Dutch populations  
*H. M. Götz, R. J. M. Born, M. Wolters, J. S. A. Fennema, I. F. van den Broek, A. G. C. L. Speksnijder, S. M. Bruisten, Rotterdam, Netherlands*

**O16.3** Controlling chlamydia: Population modeling to assess promising interventions  
*J. W. Glasser, K. Owusu-Edusei, S. N. Glick, S. O. Arol, T. L. Gift, Atlanta, United States*

**O16.4** Human papillomavirus in very young men who have sex with men and the potential benefit from vaccination  
*H. Zou, A. Morrow, S. Tabrizi, A. Grulich, S. Garland, J. Hocking, C. Bradshaw, G. Prestage, C. Fairley, M. Chen, Carlton, Australia*

**O16.5** Concordance of anal, penile, and oral human papillomavirus hr-HPV infections and HPV seropositivity in HIV-infected and HIV-negative men who have sex with men: the HIV & HPV in MSM (H2M) study  
*V. M. van Rijn, M. Mollers, S. H. Mooij, A. C. G. L. Speksnijder, A. J. King, H. J. C. de Vries, M. A. B. van der Sande, M. F. Schim van der Loeff, Amsterdam, Netherlands*

**O16.6** Pre-vaccination seroprevalence of 15 human papillomavirus (HPV) types among Slovenian women screened for cervical cancer  
*I. Klavs, V. Ušakar, M. M. Jelen, H. Faust, J. Dillner, M. Poljak, Ljubljana, Slovenia*

---

14:00 – 15:30
**Room: Trabantenstube**
**Oral Session 17 - Programme evaluation**

**Chairs:** M. Potocnik, Ljubljana, Slovenia

**O17.1** Increased HIV prevention program coverage and decline in HIV prevalence among female sex workers in south India  

**O17.2** HIV prevention at scale: has it worked? Evaluation of the impact of the Avahan programme in South India  
*M. Pickles, M. Bolly, P. Vickerman, C. M. Lowndes, S. Moses, J. F. Blanchard, B. M. Ramesh, R. S. Paranjape, M. Alary, London, United Kingdom*

**O17.3** Do we need to vaccinate males against HPV?  

**O17.4** Evaluating the cost effectiveness of targeted vaccination strategies to reduce incidence of HPV-related cancers and other clinical outcomes in men who have sex with men (MSM) in British Columbia, Canada  
*K. M. English, F. Marra, B. Davoudi, M. Gilbert, B. Pourbohloul, Vancouver, Canada*

**O17.5** Impact of comprehensive HIV/AIDS - Youth Peer Education Program with integrated ‘life skills’ and ‘community links’ components on knowledge, attitude and behavior of youths in 65 schools in 2 districts of Karnataka state, India  
*P. Borkar, New Delhi, India*

**O17.6** Expanded HIV Testing Program in STD Clinics Fails to Impact Diagnosis of New HIV-Positive Cases  
*P. W. Klein, L. C. Messer, R. A. Leone, W. C. Miller, Chapel Hill, United States*

---

15:30 - 16:00
**Coffee break / Exhibition / Poster viewing**
Astellas has a vision to change tomorrow. Through our commitment to providing patients with hope for a brighter future, we aim to lead the way in our areas of therapeutic expertise; focusing where medical needs remain unmet. Through innovation, Astellas will continue to identify and develop new ways to improve the health of patients.

Our aim is that we will discover tomorrow’s medical solutions to today’s healthcare problems. In this, as in everything we do, Astellas is committed to the success that comes from Changing tomorrow.
16:00 - 17:30
Room: Festsaal
Plenary Session 04

Chairs:  K. Fenton, London, United Kingdom
         C. Ison, London, United Kingdom
PL04.1  Sexual Behaviour and STIs in Men Who Have Sex with Men: A Global Perspective
         K. Mayer, Boston, United States
PL04.2  Sex Hormones, HIV Infection and Unintended Pregnancy: Ever Since Adam and Eve
         W. Cates, Chapel Hill, United States
PL04.3  Protective and Non-Protective Immunity in STIs
         G. Stingl, Vienna, Austria

17:30 - 18:00
Room: Festsaal
Debate 03 “Adolescent and Neonatal Circumcision Should Be Promoted Globally for HIV Control”

Moderator:  J. Wasserheit, Seattle, United States
Pro:  A. Tobian, Baltimore, United States
Contra:  P. Greenhouse, Bristol, United Kingdom

18:00 – 19:00
Poster Area: First Floor
Poster viewing with authors

Tracks:
P01 - Basic Sciences Track  P02 - Clinical Sciences Track
P05 - Translational and Implementation Sciences Track
P06 - Health Policy and Programme Sciences Track

18:00 – 19:00
Satellite Symposia
SEE PROGRAMME PAGE XX

ROOM | FORUM
--- | ---
18:00 - 19:00 | SAT08. New Paradigm of pMTCT using HIV and Syphilis combined diagnosis
            | Sponsored by Standard Diagnostic, Inc.
SCIENTIFIC PROGRAMME

WEDNESDAY, JULY 17, 2013
**WEDNESDAY, JULY 17, 2013**

<table>
<thead>
<tr>
<th>TIME</th>
<th>ROOM</th>
<th>FESTSAAL</th>
<th>PRINZ EUGEN SAAL</th>
<th>ZEREMONIENSAAL</th>
<th>FORUM</th>
<th>RITTERSAAL</th>
<th>GARTENSAAL</th>
<th>GEHEIME RATSTUBE</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:50 - 08:30</td>
<td></td>
<td>Hot Topics: Selected</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Poster Discussions 03</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30 - 09:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pleenary Session 05</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30 - 10:00</td>
<td></td>
<td>D.04 Population-Based</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Screening for Chlamydia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>in Asymptomatic Women</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>based on Age Should Be</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Abandoned</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 - 10:30</td>
<td></td>
<td>Coffee break /</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exhibition / Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>viewing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 - 12:00</td>
<td></td>
<td>S.13 Challenges to a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comprehensive Approach</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>to the Prevention of</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>HIV and STI among Men</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>who have Sex with Men</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>in Europe (organised by</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>ECDC)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 - 12:00</td>
<td></td>
<td>S.12 STD Vaccines and</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Correlates of Immunity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 - 13:30</td>
<td></td>
<td>Redoutensaal: The</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>American STD Association</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Awards Luncheon and</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lecture</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>See map page xx</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30 - 15:00</td>
<td></td>
<td>S.15 Sexual Networks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>and Contagion (Insights</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>from phylodynamic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>studies, behaviour</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>diffusion, social</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>media studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00 - 16:30</td>
<td></td>
<td>S.17 Scientific Tracks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Summary and Highlights</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30 - 16:45</td>
<td></td>
<td>Closing Remarks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**WEDNESDAY, JULY 17, 2013**

<table>
<thead>
<tr>
<th>ROOM</th>
<th>FESTSAAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:50 - 08:30</td>
<td>Hot Topics: Selected Poster Discussions 03</td>
</tr>
<tr>
<td>08:30 - 09:30</td>
<td>Pleanary Session 05</td>
</tr>
<tr>
<td>09:30 - 10:00</td>
<td>D.04 Population-Based Screening for Chlamydia in Asymptomatic Women based on Age Should Be Abandoned.</td>
</tr>
<tr>
<td>10:00 - 10:30</td>
<td>Coffee break / Exhibition / Poster viewing</td>
</tr>
</tbody>
</table>

**07:50 - 08:30**

*Room: Festsaal*

**Hot Topics: Selected Poster Discussions 03**

**Chairs:** D. Gökengin, Izmir, Turkey  
A. Robinson, London, United Kingdom

- **P2.069** Factors Associated with Biologic False Positive Rapid Plasma Reagin (RPR) Serologies in HIV-1-Infected Persons
  - I. Oboho, K. Gebo, R. Moore, K. G. Ghanem, Baltimore, United States

- **P3.409** Sexual health in the Adult Film Industry (AFI): Environmental Barriers and Facilitators of Sexually Transmitted Infection (STI) Transmission
  - P. Lilleston, E. Mead, D. Cernigliaro, S. G. Sherman, Baltimore, United States

- **P3.430** Doxycycline prophylaxis for syphilis in a persistently high risk HIV infected population
  - R. K. Bolan, M. Beymer, J. D. Klausner, R. Flynn, A. Leibowitz, Los Angeles, United States

- **P3.122** Hepatitis B incidence 2002-2012 and falling levels of immunity in men who have sex with men (MSM) at sexual health service, Melbourne

- **P5.032** Do fast-track asymptomatic screening pathways for men who have sex with men (MSM) lead to missed or delayed diagnoses?
  - M. Bains, A. Collister, R. Jackson, E. Clarke, R. Patel, Southampton, United Kingdom

**08:30 - 09:30**

*Room: Festsaal*

**Plenary Session 05**

**Chairs:** H. Handsfield, Seattle, United States  
R. Chan, Singapore

- **PL05.1** PrEP & Treatment as Prevention for HIV: Finding the Balance
  - J. Baeten, Seattle, United States

- **PL05.2** New Technologies in STI Diagnosis and Control: Promising Future
  - C. Gaydos, Baltimore, United States

**09:30 - 10:00**

*Room: Festsaal*

**Debate 04 “Population-Based Screening for Chlamydia in Asymptomatic Women based on Age Should Be Abandoned”**

**Moderator:** D. Martin, New Orleans, United States

**Pro:** J. Stephenson, London, United Kingdom

**Contra:** E. Hook, Birmingham, United States

**10:00 - 10:30**

*Coffee break / Exhibition / Poster viewing*
**Room:** Zeremoniensaal  
**Symposium 12 - STD Vaccines and Correlates of Immunity**

**Chairs:**  
A. Wald, Seattle, United States  
C. Cameron, Victoria, Canada

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>S12.1</td>
<td>Human Papillomavirus Vaccines - Correlates of Protection are not defined.</td>
<td>A. Williamson, Cape Town, South Africa</td>
</tr>
<tr>
<td>S12.2</td>
<td>Tales of woe: HSV vaccine and null study results.</td>
<td>A. Wald, Seattle, United States</td>
</tr>
<tr>
<td>S12.3</td>
<td>Understanding how broadly cross-neutralizing antibodies develop in HIV infection - clues for HIV vaccine development?</td>
<td>L. Morris, Johannesburg, South Africa</td>
</tr>
<tr>
<td>S12.4</td>
<td>Chlamydia trachomatis.</td>
<td>R. Johnson, Indianapolis, United States</td>
</tr>
</tbody>
</table>

**Room:** Prinz Eugen Saal  
**Symposium 13 - Challenges to a Comprehensive Approach to the Prevention of HIV and STI among Men who have Sex with Men in Europe (organised by ECDC)**

**Chairs:**  
M. van de Laar, Stockholm, Sweden,  
K. Fenton, England, United Kingdom

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>S13.2</td>
<td>Evidence-based targeted review of HIV and STI prevention interventions among MSM</td>
<td>A. Thorson, Stockholm, Sweden</td>
</tr>
<tr>
<td>S13.3</td>
<td>The status of HIV prevention among MSM: an overview of the European response.</td>
<td>O. Sfetcu, Stockholm, Sweden</td>
</tr>
<tr>
<td>S13.4</td>
<td>What do gay men need? – Challenges regarding comprehensive approaches in HIV-prevention interventions from a national perspective.</td>
<td>D. Sander, Berlin, Germany</td>
</tr>
</tbody>
</table>

**Roundtable discussion: Improving disease prevention among MSM: barriers and challenges**

**Room:** Forum  
**Symposium 14 - New strategies and implementation of best practices for dual elimination of mother-to-child transmission of syphilis and HIV (organised by WHO)**

**Chairs:**  
N. Broutet (WHO, Switzerland),  
L. Khotenashvili (WHO, Copenhagen)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>S14.1</td>
<td>Understanding the impact of timing of treatment in pregnancy and associated adverse outcomes in Mozambique</td>
<td>M. Mussagy, Maputo, Mozambique</td>
</tr>
<tr>
<td>S14.2</td>
<td>The CISNE Project: Implementation of POCT for syphilis and HIV in antenatal care and reproductive health services in Peru</td>
<td>P. Garcia, Lima, Peru</td>
</tr>
<tr>
<td>S14.3</td>
<td>Explaining inaction: the politics of congenital syphilis and the global health agenda</td>
<td>J. Bump, Georgetown, United States, N. Salisbury, Seattle, United States</td>
</tr>
<tr>
<td>S14.4</td>
<td>Monitoring the finish-line: integrated global criteria and processes for validation of EMTCT of syphilis and HIV</td>
<td>L. Newman, Geneva, Switzerland</td>
</tr>
<tr>
<td>S14.5</td>
<td>Piloting methods for validation of elimination of MTCT of HIV and syphilis in St. Lucia and Chile</td>
<td>K. Hoover, Atlanta, United States</td>
</tr>
<tr>
<td>ROOM</td>
<td>RITTERSAAL</td>
<td>GARTENSAAL</td>
</tr>
<tr>
<td>--------------</td>
<td>------------------------------------------------------</td>
<td>------------------------------------------------------</td>
</tr>
<tr>
<td>10:30 - 12:00</td>
<td>O.18 Diagnosis of sexually transmitted infections</td>
<td>O.19 Prevention and Curing STIs: Who is the Winner?</td>
</tr>
</tbody>
</table>

**10:30 – 12:00**

**Room: Rittersaal**

**Oral Session 18 - Diagnosis of sexually transmitted infections**

**Chairs:** H. de Vries, Amsterdam, The Netherlands
H. Moi, Oslo, Norway

**O18.1** Molecular techniques for differentiation of the T. pallidum subspecies and specimen collection with FTA Elute cards
C. Chen, K. Chi, A. Pillay, Atlanta, United States

**O18.2** 3 in 1 Study: Pooling self-taken pharyngeal, urethral and rectal samples into a single sample
B. J. Sultan, R. Fish, G. Carrick, R. Gilson, N. Brima, A. Robinson, D. Mercer, J. White, P. Benn, London, United Kingdom

**O18.3** Utility of cerebrospinal fluid analysis in the investigation and treatment of neurosyphilis
M. L. Roy, M. Rayment, A. Sullivan, M. Nelson, London, United Kingdom

**O18.4** Lack of vital capacity of Chlamydia trachomatis in fallopian tubes of patients with ectopic pregnancy
M. S. van Rooijen, M. F. Schim van der Loeff, D. Kwa, G. Jansen, H. de Vries, Amsterdam, Netherlands

**10:30 – 12:00**

**Room: Gartensaal**

**Oral Session 19 - Prevention and Curing STIs: Who is the Winner?**

**Chairs:** S. Garland, Parkville, Australia
G. Bolan, Atlanta, United States

**O19.1** Azithromycin and Doxycycline Resistance Profiles of Mycoplasma genitalium and Association with Treatment Outcomes

**O19.2** Mycoplasma genitalium is as frequent a cause of urethritis as Chlamydia trachomatis, and has high rates of genotypic resistance to macrolide antibiotics

**O19.3** Estimate of the prevalence of transmitted drug resistance (TDR) and acquired drug resistance (ADR) in a HIV resistance study of the German ClinSurv-HIV cohort

**O19.4** Acceptability of HPV Vaccination among Parents of Adolescent School Going Girls in Mysore City, India
K. Krupp, V. Srinivas, L. Marlow, T. Li, A. Albetini, S. Gowda, A. Arun, P. Jayakrishna, P. Madhihavan, Mysore, India

**O19.5** Assessing the effectiveness of the Human Papillomavirus (HPV) vaccination program in Victoria, Australia

**O19.6** Use of surfactant vesicles as a potential gonococcal vaccine delivery system to generate antibody against neisserial Lipoooligosaccharide
D. Stein, L. Zimmerman, J. Park, L. Stocker, P. DeShong, College Park, United States

**10:30 – 12:00**

**Room: Geheime Ratstube**

**Oral Session 20 - Sexual Partnerships and Networks**

**Chairs:** W. Cates, Chapel Hill, United States
H. David, Bethesda, United States

**O20.1** Two-mode analysis of HIV, HCV and risk behaviours: a place-based analysis of most at-risk populations in Winnipeg, Canada
S. Y. Shaw, C. Green, J. L. Wylie, Winnipeg, Canada

**O20.2** Social networks of STI patients have higher STI prevalence than social networks of community controls

**O20.3** Sex in Seattle: Mechanistic modelling of sexual partnership dynamics
J. W. Glasser, H. W. Chesson, S. N. Glick, K. Owusu-Edusei, T. L. Gift, S. O. Aral, Atlanta, United States

**O20.4** Daily variation in feelings of intimacy predict incident STI within a prospective study of urban adolescent females
P. A. Matson, S. Chung, C. A. Gaydos, J. M. Ellen, Baltimore, United States

**O20.5** Patterns of sexual and social mixing among heterosexual couples living together in England: Analyses of a probability sample survey

**O20.6** Sexual partnership patterns among young people in rural Tanzania
A. M. Doyle, J. Changalucha, H. A. Weiss, D. Watson-Jones, R. J. Hayes, B. Zaba, A. Ross, London, United Kingdom
**12:00 - 13:30**

**Room: Redoutensaal**

**The American STD Association Awards Luncheon and Lecture**

- **Young Investigator Award:** Dr. Jesse Clark
- **Achievement Award:** Dr. Jane Schwebke
- **Distinguished Career Award:** Dr. Jonathan Zenilman

"The Historical Legacy of STD Research - Lessons from Guatemala and Dr. Thomas Parran"

SEE MAP PAGE XX

---

<table>
<thead>
<tr>
<th>ROOM</th>
<th>PRINZ EUGEN SAAL</th>
<th>ZEREMONIENSAAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30 - 15:00</td>
<td>S.15 Sexual Networks and Contagion (Insights from phylodynamic studies, behaviour diffusion, social media studies)</td>
<td>S.16 Challenging Clinical Conditions</td>
</tr>
</tbody>
</table>

---

**13:30 – 15:00**

**Room: Prinz Eugen Saal**

**Symposium 15 - Sexual Networks and Contagion (Insights from phylodynamic studies, behaviour diffusion, social media studies)**

- **Chairs:** M. Hobgen, Atlanta, United States  
  J. Jennings, Baltimore, United States

  - **S15.1** Frequent viral introductions sustain local HIV epidemics in rural Africa.  
    K. Grabowski, Baltimore, United States
  - **S15.2** Social networking and diffusion of risks and interventions among youth.  
    S.D. Young, Los Angeles, United States
  - **S15.3** Modification of sexual networks and sexual risk for men having sex with men (MSM) by the Internet.  
    U. Marcus, Berlin, Germany
  - **S15.4** Discussant. Implications of Sexual Networks.  
    J. Jennings, Baltimore, United States

---

**13:30 – 15:00**

**Room: Zeremoniensaal**

**Symposium 16 - Challenging Clinical Conditions**

- **Chairs:** J. Wilson, Leeds, United Kingdom  
  J. Schwebke, Birmingham, United States

  - **S16.1** Recurrent and persistent urethritis in men - a structured evidence based approach to management.  
    P. Horner, Bristol, United Kingdom
  - **S16.2** Recurrent BV.  
    J. Marrazzo, Seattle, United States
  - **S16.3** Recurrent TV: The potential of molecular techniques to improve clinical practice.  
    M. Hobbs, Chapel Hill, United States
  - **S16.4** Lymphogranuloma venereum in Men who have Sex with Men. An ongoing epidemic since 10 years, but still not tackled.  
    H. De Vries, Amsterdam, The Netherlands
  - **S16.5** Management of syphilis in pregnancy.  
    J. Wilson, Leeds, United Kingdom
<table>
<thead>
<tr>
<th>ROOM</th>
<th>FORUM</th>
<th>RITTERSAAL</th>
<th>GARTENSAAAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30 - 15:00</td>
<td></td>
<td>O.21 Antimicrobial Resistance Mechanisms in STI Pathogens</td>
<td>O.22 Alternative screening tools and screening sites</td>
</tr>
</tbody>
</table>

**13:30 – 15:00**

**Room: Forum**

**O.21 Antimicrobial Resistance Mechanisms in STI Pathogens**

**Chairs:**

- M. Unemo, Örebro, Sweden
- F. Sparling, Chapel Hill, United States

**O21.1**

Mykoplasma genitalium infectious load and treatment failure due to selected macrolide resistance

- J. Twin, C. Bradshaw, S. Garland, M. Bissessor, M. Chen, J. Walker, C. Fairley, J. Hocking, S. Tabrizi, Melbourne, Australia

**O21.2**

Effect of mutations in pilQ on the susceptibility of Neisseria gonorrhoeae to cephalosporins

- K. Petti, S. Johnson, Atlanta, United States

**O21.3**

Fitness studies on Neisseria gonorrhoeae harboring mosaic penA alleles from ceftriaxone-resistant isolates predict the spread of resistance to extended-spectrum cephalosporins

- L. R. Vincent, M. Unemo, M. Duncan, R. A. Nicholas, A. E. Jerse, Bethesda, United States

**O21.4**

In vitro synergy determination for dual antibiotic therapy against resistant Neisseria gonorrhoeae using Etest® and agar dilution

- C. M. Wind, H. J. C. de Vries, A. P. van Dam, Amsterdam, Netherlands

**O21.5**

Understanding the molecular mechanism of mtrR in the regulation of antimicrobial resistance in Neisseria gonorrhoeae using in vitro and in silico studies

- D. Sachdev, I. Kumar, M. Chopra, L. R. Singh, D. Saluja, Delhi, India

**O21.6**

A Tale of Two Cities: Treponema pallidum Macrolide Resistance in Colombo (Sri Lanka) and London (United Kingdom)


**13:30 – 15:00**

**Room: Rittersaal**

**O.22 Alternative screening tools and screening sites**

**Chairs:**

- J. Schachter, San Francisco, United States
- B. van der Pol, Indianapolis, United States

**O22.1**

Evaluation of Syphilis point of care tests conducted by midwives at primary health facilities in Ghana


**O22.2**

Direct and indirect effects of screening for Chlamydia trachomatis on the prevention of pelvic inflammatory disease: mathematical modeling study

- S. A. Herzog, J. C. M. Heijne, P. Scott, C. L. Althaus, N. Low, Graz, Austria

**O22.3**

Texting Improves notification of Sexually Transmitted Infection Results after Emergency Department Visits

- J. Reed, J. S. Huppert, R. Taylor, G. Gillespie, T. Byczkowski, J. Kahn, E. Alessandri, Cincinnati, United States

**O22.4**

What are young people's perceptions of using electronic self-tests for STIs linked to mobile technology for diagnosis and care (eSTI2)?


**O22.5**

Providing discrete and reliable STD testing in Alaska via a web-based at-home service

- B. Simons, C. Jessen, L. Rea, M. Barnes, P. Barnes, C. Gaydos, Anchorage, United States

**O22.6**

Field evaluation of three point-of-care tests for chlamydia and gonorrhoea in remote health services in Australia


**O22.7**

Home-based sample collection increases chlamydia retesting and detects additional repeat positive tests: a randomised controlled trial in three risk groups


**13:30 – 15:00**

**Room: Gartensaal**

**O.23 Risk Behaviors and Preventive Interventions**

**Chairs:**

- K. Fenton, London, United Kingdom
- M. Waugh, Leeds, United Kingdom

**O23.1**

Sexual risk trajectories among MSM in the United States: implications for PrEP delivery

- H. A. Pines, R. M. Gorbach, R. E. Weiss, S. Shoptaw, D. G. Ostrow, R. D. Stall, M. Plankey, Los Angeles, United States

**O23.2**

Correlates of inconsistent condom use during anal sex with female sex workers (FSWs) among male clients: Survey findings from three high prevalence states of India

- S. Ramanathan, A. V. Marcell, N. Nakyanjo, L. Leonard, M. J. Wawer, Baltimore, United States

**O23.3**

Predictors of self-assessed risk of Chlamydia trachomatis infection among adolescents in Norway

- K. Gravningen, H. Schirmer, A. Furberg, G. S. Simonsen, T. Wilskaag, Tromsø, Norway

**O23.4**

Understanding domestic violence as a predictor of adverse health outcomes and sexual risk-taking among men who have sex with men (MSM): a systematic review and meta-analysis

- A. Buller, L. Bacchus, K. Devries, London, United Kingdom

**O23.5**

“Circumcision Makes Them Half Men”: Concerns about Loss of Masculinity May Deter Acceptance of Safe Medical Male Circumcision

- J. S. Huppert, J. Reed, R. Taylor, G. Gillespie, T. Byczkowski, J. Kahn, E. Alessandri, Cincinnati, United States

**O23.6**

Factors that influence contraceptive choice and use among HIV discordant couples in Kisumu, Kenya

- J. B. Odoyo, B. Rono, K. Owuor, C. R. Cohen, E. A. Bukusi, Nairobi, Kenya
Joining forces to deliver extraordinary care

Now working as one company, Hologic and Gen-Probe are bringing together a comprehensive suite of best-in-class diagnostic products. As a leader in cytology and molecular technologies, we have thoughtfully blended engineering and science to deliver superior STI assays and flexible workflow automation with accurate and reliable results.

Visit the Hologic stand, HOFBURG Galerie - First Level to experience the power of the new Hologic and the promise of what’s to come.

Hologic. Every life is extraordinary.

PLEASE JOIN US

Hologic Lunch Satellite Symposium
Comparison and Clinical Application of Instrumentation Platforms and Assays for STI Detection

Monday, July 15, 2013
13:00 - 14:00, Hall FORUM

www.hologic.com
15:00 – 16:30
Room: Festsaal
S17 – Scientific Tracks: Summary and Highlights

Chairs: A. Stary, Vienna, Austria
T. Quinn, Baltimore, United States

S17.1 Basic Science
Rapporteur: D. Lewis, Sandringham, South Africa

S17.2 Clinical Science
Rapporteur: K. Radcliffe, Birmingham, United Kingdom

S17.3 Epidemiology and Prevention Sciences
Rapporteur: J. Marrazzo, Seattle, United States

S17.4 Social and Behavioural Sciences
Rapporteur: H. Ward, London, United Kingdom

S17.5 Implementation Science
Rapporteur: G. Bolan, Atlanta, United States

S17.6 Programme Science and Policy
Rapporteur: J. Blanchard, Winnipeg, Canada

16:30 – 16:45
Room: Festsaal
Closing Remarks and Announcement of the World STI & AIDS 2015, Brisbane Australia

Chairs: A. Stary, Vienna, Austria
C. Heller-Vitouch, Vienna, Austria
B. Donovan, Sydney, Australia
D. Lewis, Sandringham, South Africa
SATELLITES SYMPOSIA
BOARD MEETINGS
SIDE MEETINGS
SATELLITE SYMPOSIA

TUESDAY, JULY 16, 2013

12:00 – 13:00
Room: Zeremoniensaal
Satellite Symposium 06 - Quadriivalent Vaccine Symposium: Optimizing Strategies for Protecting Girls and Boys Against HPV Cancers and Other Related Diseases
Lunch Satellite Symposium sponsored by MSD / SPMSD
A light lunch will be offered to the attendees in front of the Zeremoniensaal
Chairs: E. Joura, Vienna, Austria
J. Paavonen, Helsinki, Finland
Welcome/Introduction
J. Paavonen, Helsinki, Finland
SAT06.1 Burden of HPV Disease in Males
J. Palefsky, San Francisco, United States
SAT06.2 Clinical Efficacy & Long Term Follow Up Data
E. Joura, Vienna, Austria
SAT06.3 Real World Impact & Best Practices for HPV Implementation
A. Grulich, Darlinghurst, Australia
Q&A/Conclusion
E. Joura, Vienna, Austria

13:00 – 14:00
Room: Zeremoniensaal
Satellite Symposium 07 - Xpert® CT/NG: Molecular Testing for Control Freaks
Lunch Satellite Symposium sponsored by Cepheid
A light lunch will be offered to the attendees in front of the Zeremoniensaal
Chair: D. Persing, Sunnyvale, United States
C. Gaydos, Baltimore, United States
SAT07.1 Analytical evaluation of the GeneXpert® CT/NG
S. Tabrizi, Melbourne, Australia
SAT07.2 Results for Today: Screening women quickly for CT/GC using the Xpert assay
B. Van Der Pol, Indianapolis, United States
SAT07.3 Next Generation NAATS for STI Management - Into the future with the XPert CT/NG
E. N. Hook III, Birmingham, United States

18:00 – 19:00
Room: Forum
Satellite Symposium 08 - New Paradigm of pMTCT using HIV and Syphilis combined diagnosis
Symposium sponsored by Standard Diagnostic, Inc.
Chair: (Dr. Rosanna Peeling – TBD)
SAT08.1 Global problem of maternal HIV and syphilis – why is that important
J. D. Klausner, Los Angeles, United States
SAT08.2 UN efforts to eliminate maternal-to-child transmission of HIV and syphilis
J. D. Klausner, Los Angeles, United States
SAT08.3 The use of dual rapid combined HIV and syphilis tests
J. D. Klausner, Los Angeles, United States
SAT08.4 Performance of dual rapid combined HIV and syphilis tests
R. Ondondo
18:00 – 19:00
Room: Prinz Eugen Saal
Satellite Symposium 04 - Bacterial STIs in Europe

Satellite Symposium sponsored by Astellas Europe B.V

Chairs:  
M. Gomberg, Moscow, Russia  
A. Stary, Vienna, Austria

SAT04.1 Treatment of bacterial STI: interesting alternatives  
M. Cusini, Milano, Italy
SAT04.2 Is C. trachomatis infection still important in Europe?  
M. Skerlev, Zagreb, Croatia
SAT04.3 Bacterial STI in Europe: is there a difference between East and West?  
A. Põder, Tartu, Estonia
SAT04.4 Prevalence of Ureaplasma urealyticum in women with risk of miscarriage  
V. N. Prilepskaya, I. Y. Fofanova, Moscow, Russia
SAT04.5 Is M. genitalium a second common bacterial STI? Russian experience in diagnostic and treatment  
A. Y. Gushin, M. Gomberg, Moscow, Russia

18:00 – 19:00
Room: Forum
Satellite Symposium 05 - Molecular Diagnostics: A Syndromic Approach to STI & Vaginitis Testing

Where should Trichomonas vaginalis be included?

Satellite Symposium sponsored by BD Diagnostics

Chair:  
J. White, London, United Kingdom

SAT05.1 The Clinical Picture of Vaginitis and Selected STIs  
J. Schwebke, Birmingham, United States
SAT05.2 Molecular Testing : The Newest Technology to Diagnose Vaginitis & STIs  
B. Van Der Pol, Indianapolis, United States

BD Molecular STI Testing
Simply the most comprehensive solution

For more than a century, BD has been dedicated to tackling some of the world’s health-care challenges. Sexually transmitted infection incidence rates remain high in most of the world and they might be even higher since many are not diagnosed due to lack of appropriate methods. BD is committed to providing a range of solutions to support the fight against these diseases providing relevant clinical answers while using efficient and worry free technologies.

Learn more about BD’s vision at our symposium on

Molecular Diagnostics: A Syndromic Approach to STI & Vaginitis Testing
Where should Trichomonas vaginalis be included?

on Monday July 15th, 18:00 – 19:00h – FORUM hall
SATELLITE SYMPOSIA

TUESDAY, JULY 16, 2013

12:00 – 13:00
Room: Zeremoniensaal
Satellite Symposium 06 - Quadrivalent Vaccine Symposium: Optimizing Strategies for Protecting Girls and Boys Against HPV Cancers and Other Related Diseases

Lunch Satellite Symposium sponsored by MSD / SPMSD
A light lunch will be offered to the attendees in front of the Zeremoniensaal

Chairs: E. Joura, Vienna, Austria
J. Paavonen, Helsinki, Finland

Welcome/Introduction
J. Paavonen, Helsinki, Finland

SAT06.1 Burden of HPV Disease in Males
J. Palefsky, San Francisco, United States

SAT06.2 Clinical Efficacy & Long Term Follow Up Data
E. Joura, Vienna, Austria

SAT06.3 Real World Impact & Best Practices for HPV Implementation
A. Grulich, Darlinghurst, Australia
Q&A/Conclusion
E. Joura, Vienna, Austria

13:00 – 14:00
Room: Zeremoniensaal
Satellite Symposium 07 - Xpert® CT/NG: Molecular Testing for Control Freaks

Lunch Satellite Symposium sponsored by Cepheid
A light lunch will be offered to the attendees in front of the Zeremoniensaal

Chair: D. Persing, Sunnyvale, United States
C. Gaydos, Baltimore, United States

SAT07.1 Analytical evaluation of the GeneXpert® CT/NG
S. Tabrizi, Melbourne, Australia

SAT07.2 Results for Today: Screening women quickly for CT/GC using the Xpert assay
B. Van Der Pol, Indianapolis, United States

SAT07.3 Next Generation NAATS for STI Management - Into the future with the XPert CT/NG
E. N. Hook III, Birmingham, United States

18:00 – 19:00
Room: Forum
Satellite Symposium 08 - New Paradigm of pMTCT using HIV and Syphilis combined diagnosis

Symposium sponsored by Standard Diagnostic, Inc.

Chair: (Dr. Rosanna Peeling – TBD)

SAT08.1 Global problem of maternal HIV and syphilis – why is that important
J. D. Klausner, Los Angeles, United States

SAT08.2 UN efforts to eliminate maternal-to-child transmission of HIV and syphilis
J. D. Klausner, Los Angeles, United States

SAT08.3 The use of dual rapid combined HIV and syphilis tests
J. D. Klausner, Los Angeles, United States

SAT08.4 Performance of dual rapid combined HIV and syphilis tests
R. Ondondo
<table>
<thead>
<tr>
<th><strong>Saturday, July 13, 2013</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ISSTDR Board Meeting</td>
<td>09:00 - 13:00</td>
</tr>
<tr>
<td>IUSTI Executive Meeting</td>
<td>14:00 - 18:00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Sunday, July 14, 2013</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>IUSTI-Europe Council Meeting</td>
<td>10:00 - 14:00</td>
</tr>
<tr>
<td>IUSTI Guidelines Meeting (European STI Guidelines Editorial Board)</td>
<td>15:00 - 16:30</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Monday, July 15, 2013</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>STI &amp; AIDS World Congress Press Conference</td>
<td>10:30 - 12:00</td>
</tr>
<tr>
<td>Journal of Sexually Transmitted Infections - Board Meeting</td>
<td>12:00 - 13:30</td>
</tr>
<tr>
<td>GASP Meeting</td>
<td>16:30 - 18:00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Tuesday, July 16, 2013</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sexually Transmitted Diseases - 2013 Editorial Board meeting</td>
<td>12:30 – 13:45</td>
</tr>
<tr>
<td>IUSTI World General Assembly</td>
<td>13:00 - 14:00</td>
</tr>
<tr>
<td>Roche Meet the Experts</td>
<td>15:30-16:00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Wednesday, July 17, 2013</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Dual elimination of MTCT of HIV and syphilis: WHO Expert Group Meeting, BASTA.</td>
<td>07:00 - 08:30</td>
</tr>
</tbody>
</table>
Quadrivalent Vaccine Symposium: Optimizing Strategies for Protecting Girls and Boys Against HPV Cancers and Other Related Diseases

Tuesday, 16 July 2013
12:00 – 13:00

Hofburg Congress Center
Room: Zeremoniensaal
Vienna, Austria

Chairs: Elmar Joura
Jorma Paavonen

AGENDA

12:00 – 12:05 Welcome/Introduction
Jorma Paavonen

12:05 – 12:20 Burden of HPV Disease in Males
Joel Palefsky

12:20 – 12:35 Clinical Efficacy and Long-term Follow-up Data
Elmar Joura

12:35 – 12:50 Real World Impact and Best Practices for HPV Implementation
Andrew Grulich

12:50 – 13:00 Q&A/Conclusion
Elmar Joura
PROGRAMME CHANGES

The organiser cannot assume any liability for changes in the programme due to external or unforeseen circumstances.

PUBLICATION

Please note that your work will be published in the journal of *Sexually Transmitted Infections* in the July 2013 Volume 89 Supplement 1.

POSTERS

Topics

- P01 - Basic Sciences Track: P1.001 - P1.045
- P02 - Clinical Sciences Track: P2.001 - P2.196
- P03 - Epidemiology and Prevention Sciences Track: P3.001 - P3.449
- P04 - Social and Behavioural Sciences Track: P4.001 - P4.152
- P05 - Translational and Implementation Sciences Track: P5.001 - P5.110
- P06 - Health Policy and Programme Sciences Track: P6.001 - P6.076

Format

The usable surface on the poster board will be **90 cm width x 130 cm height** (approx. 35 x 51 inches). Upright format.

Mounting and Removal

- **Poster mounting** will be possible on: **Monday, July 15, 2013, from 07.30 - 15.00 hrs**
- **Removal** will be possible on: **Wednesday, July 17, 2013, from 10.30 hrs - 15.00 hrs**

The organisers cannot assume any liability for loss or damage of posters displayed in the poster area. Please note that posters not removed by Wednesday, July 17, 2013 by 16:30 hrs will be taken down by the staff of the conference center and will not be stored or sent to the authors after the meeting.

Presence at Posters

In order to enable discussion and interaction with other participants, we request you (or one of your group) to be at your poster board for the following sessions:

**Poster Session 1**
- Monday, July 15, 2013 – 18:00 – 19:00 for the following poster topics:
  - P03 - Epidemiology and Prevention Sciences Track
  - P04 - Social and Behavioural Sciences Track

**OR**

**Poster Session 2**
- Tuesday, July 16, 2013 – 18:00 – 19:00 for the following poster topics:
  - P01 - Basic Sciences Track
  - P02 - Clinical Sciences Track
  - P05 - Translational and Implementation Sciences Track
  - P06 - Health Policy and Programme Sciences Track

If this is not possible, please leave a note on your poster board detailing the times when you will be present at the board.

ORAL POSTER PRESENTATIONS

Abstracts selected for an oral poster presentations are posters which will also be presented by their authors in a short oral presentation during the “Hot Topic” Sessions.

Speaking Time

3 minutes presentation time, discussion time will be available at the end of the session.

Preparation

For the presentation of your poster, you have been asked to prepare the following:

- A **power point presentation** (maximum 3 slides) for the oral presentation of your poster
- A **poster** that will be mounted onsite in the poster exhibition

The surface on the poster board is **90 cm width x 130 cm height** (approx. 35 x 51 inches) and your poster should be in upright format.
ORAL PRESENTATIONS

Slide Preview Room
It is essential that you load and view your presentations in the preview room preferably in the morning before your talk, but no later than 2 hours in advance.
The preview center is situated on the first floor of the congress center in Room Künstlerzimmer

<table>
<thead>
<tr>
<th>Opening Hours Slide Preview Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, July 14, 2013</td>
</tr>
<tr>
<td>07:30 – 19:00 hrs</td>
</tr>
<tr>
<td>Monday, July 15, 2013</td>
</tr>
<tr>
<td>07:00 – 19:00 hrs</td>
</tr>
<tr>
<td>Tuesday, July 16, 2013</td>
</tr>
<tr>
<td>07:00 – 19:00 hrs</td>
</tr>
<tr>
<td>Wednesday, July 17, 2013</td>
</tr>
<tr>
<td>07:00 – 15:30 hrs</td>
</tr>
</tbody>
</table>

Speaking Time
15 minutes slots a maximum of 10 minutes speaking time and 5 minutes discussion time.
The chairpersons of your session will be strict in allowing no more than the time allotted to your paper. Please remember to allow some time for the changeover of speakers and chairpersons introduction and for questions and discussion.

Please rehearse your talk to make sure it will fit comfortably into the available time.
Please note that, as a rule, presenters can show a (final) slide with all acknowledgements, however, in view of the short time available, names cannot be read to the audience.
Make yourself known to the chairpersons and/or the room assistant in your session room before the beginning of the session.

Projection and Technical Setting
- All rooms will be equipped with data-projection (no slides).
- The lecture rooms are exclusively equipped with Windows-PCs (no Macintosh machines). Should you absolutely have to use your own laptop or notebook, please contact the congress office in advance.
- Please bring a USB-stick, CD-ROM or floppy disk all formatted for Windows® (PC). You may want to carry a second disk/CD as a back-up in case there is any insoluble technical problem.
- File Format: Microsoft® Power Point™ presentation formatted for Windows® (PC) only. (Operating system: Windows XP®)
- Preferred Resolution: XGA (1024 x 768 pixel)

External Genital Warts Treatment
A gentle genital approach with low recurrence rate

Cream, 5% Aldara
Imiquimod
Badges
Participants should collect name badges from the conference registration desk. Since only registered participants will be permitted to
attend the scientific sessions, the exhibition and poster areas, you are kindly asked to wear your badge when entering the congress venue.
Accompanying persons and exhibitors will also receive badges to allow access to the respective areas.
Lost badges can be replaced at the registration desk. However, a handling fee of EURO 30.- will be charged.

Car parking
Reserved parking space can be found around the congress venue. A very limited number of parking slots will be made available directly in
front of the HOFBURG Congress Center. We offer this service on a first come, first served basis. However, please be aware that if you park on
a reserved parking space, your car will be almost immediately towed away. Numerous parking garages are also available around the city
center.

Certificate of attendance
The certificates of attendance are issued at the registration desk. You will receive it at the same time as you register or pick-up your regis-
tration material. If you need an additional “confirmation of poster presentation” or “confirmation of oral presentation”, please inform the
registration desk manager who will have it prepared for pick-up at a agreed on time.

Cancellations and refunds
Notice of cancellation must be made in writing by registered letter or fax to the Congress Office.
Registration fees may be refunded as follows:
Written cancellation received:
- before April 21, 2013: 75% refund
- between April 22 and June 09, 2013: 25% refund
- after June 10, 2013: no refund
The date of the postmark or fax ID is the basis will be the basis for considering refunds. Refunds will be made after the congress.

Cloakroom and luggage
A cloakroom and luggage storage facilities are available in the congress venue.

Coffee breaks
During the session breaks refreshments (coffee, tea, and water) will be served free of charge to participants wearing name badges. Coffee
breaks will take place in the exhibition and poster areas.

Currency
The official currency of Austria is the Euro (€). 1 EURO = 1.28 USD = 0.84 GBP = 132.24 JPY = 1.24 CHF = 7.89 CNY (as per date of printing)

Drinking water
Tap water in Austria is of very good quality and can be used without concern.

Internet
Free WiFi will be available throughout the congress center.
SYMPOSIUM IS CHAIRED BY
Prof. Georg Stingl
Prof. Norbert Brockmeyer

TALKS

SEX
50 years of SEX, Sexual Behavior and Epidemiology of STIs: 1963 – 2013
Dr. Stefan Esser

DRUGS
Development towards modern HIV Therapies
Dr. Ninon Taylor

ROCK’N’ROLL
Today’s HIV Therapies: Impact on Sexual Behavior?
Dr. Carl Knud Schewe

Monday, July 15, 2013
12.00 am – 1.00 pm
Hofburg Congress Center, Zeremoniensaal

A light lunch will be served prior to the Symposium in front of Zeremoniensaal.
Insurance
In registering for the STI & AIDS World Congress 2013 participants agree that neither the organising committee nor the congress office assume any liability whatsoever. Participants are requested to make their own arrangements for health and insurance.

Language
The official language of the congress will be English (no simultaneous translation provided).

Lunches
Lunchboxes will be served at the lunchtime satellite symposia organised by the sponsoring companies. The congress will not serve lunch.

Message board
Message boards are available in the registration area.

Telephone
For international calls to Austria, dial the international code (+43) and the correspondent's number without the 0. For international calls from Austria, dial your correspondent's international code and number.

Programme changes – Access to sessions
The conference organisers reserve a right to modify the programme and cannot assume any liability for changes in the programme due to external or unforeseen circumstances. No refunds can be granted in case of cancellation of speakers, lack of space in the conference room or any other incidents during the conference which are beyond the control of the conference organiser.

Public transport
Vienna’s public transport network covers 937 km. The five subway lines, 28 tram lines and 90 bus lines bring you quickly and reliably to your destination. The tickets are valid in all trams, buses and subways of the Vienna Transport Authority. Each stamped ticket is valid up to the destination, including (several) transfers. The tickets can be bought at every underground station or in every tabacco shop (Traffic). The rates are as follows: Single ticket € 2.00 (Children € 1.00); 24-hour Vienna ticket € 6.70; 48-hour Vienna ticket € 11.70; 72-hour Vienna ticket: € 14.50; Vienna weekly ticket (only valid from Monday to Monday at 9:00 am) € 15.00. Single tickets can also be purchased directly in buses and trams but for a higher price of € 2.20 (children: € 1.10). They are valid for one ride including transfers. Children up to six years of age travel for free. Children up to fifteen years of age ride free on Sundays, holidays and during the Vienna school holidays.

Staff
Should you have any questions, congress staff will be pleased to help you. Please contact the registration desk.

Taxis in Vienna
If you do not wish to use the public transport, you can also use one of the numerous taxis waiting at one of the taxi stands or simply hire one on the street. If you wish to call a taxi the following numbers will contact you to the Taxiservices in and around Vienna: (0043) 1 60160 or (0043) 1 40100 or (0043) 1 31300.

Tourist Information
The nearest tourist information point to the congress center is located in the 1st district in the city center: Albertinaplatz, corner of Maysedergasse 1010 Vienna
It is open daily from 09:00hrs to 19:00hrs
www.wien.info

Travelling to HOFBURG by public transport
The Hofburg is located in the centre of the Old Town and can easily be reached with public transport. Two underground stations, and bus and tram stops are within walking distance. Reserved parking is also available nearby.
Underground line U3: station “Herrengasse”, walk to Hofburg 5 min
Tramway lignes 1, 2 or D: station “Burgring”, walk to Hofburg 3 min
City Bus 2A: bus stop “Heldenplatz”, walk to Hofburg 3 min

V.A.T.
A value-added tax (V.A.T.) of 10% (food) to 20% (other items) is applied to all products and services. In most cases it is included in the price. Whenever it is not included, however, it will be clearly specified.
What is covered by the registration fees?
Admission to all scientific sessions
Admission to the industry exhibition
All conference material (final programme, abstract book, bag…)
Coffee breaks

Children and Accompanying Persons
Children and members of the public are not permitted in the exhibition area or any room hosting an industry activity. In addition, the STI & AIDS World Congress 2013 asks delegates and faculty to refrain from taking children and accompanying adults to any scientific sessions or practical demonstrations. In the event that children are required to enter the Congress Centre they should be supervised by an adult at all times and observe the restrictions that apply to limited access areas. In the event that a member of public is invited to participate in the STI & AIDS World Congress 2013 Congress scientific programme, they should be accompanied by a qualified healthcare professional or STI & AIDS World Congress 2013 representative observing the STI & AIDS World Congress 2013 restrictions where appropriate.

Cancellations and refunds
Notice of cancellation must be made in writing by registered letter or fax to the Congress Office.
Registration fees may be refunded as follows:
Written cancellation received:
- before April 21, 2013: 75% refund
- between April 22 and June 09, 2013: 25% refund
- after June 10, 2013: no refund
The date of the postmark or fax ID will be the basis for considering refunds. Refunds will be done after the congress.
After the Opening Ceremony, you will be served refreshments and fingerfood in the exhibition area of the congress center. Registration is mandatory!

**Networking Event at the Congress Center**

**Sunday, July 14, 2013**

**19:30 – 21:00 hrs**

After the Opening Ceremony, you will be served refreshments and fingerfood in the exhibition area of the congress center. Registration is mandatory!

**Gala Dinner at the Vienna City Hall**

**Tuesday, July 16, 2013**

**19:30 – 24:00 hrs**

Address: **Vienna City Hall**

Lichtenfelsgasse 2, 1010 Vienna

The mayor and governor of Vienna is pleased to invite you to a Gala Dinner at the Vienna City Hall.

Meet your colleagues at the City Hall and enjoy the evening with buffet and live music. Registration is mandatory in order to receive a ticket.

Limited attendance!

Dress code: casual smart
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need such as HIV, hepatitis, fungal infections, cystic fibrosis and oncology. Today our portfolio includes the only complete treatment regimens for HIV infection available in a once-daily single pill. Since 2003, we have provided our HIV medicines at substantially reduced prices in 130+ low and lower middle-income countries through the Gilead Access Program, and signed non-exclusive licenses with multiple generic manufacturers. As a result of this program, approximately 3.5 million patients in the developing world are now receiving Gilead’s therapies. Gilead was the first company to sign an agreement with the Medicines Patent Pool.

Building upon the legacy of pioneers like Louis Pasteur we want to help protect people against infectious diseases so that they can live longer, feel better and achieve more. We are dedicated exclusively to vaccines because we believe prevention is better than cure and immunisation is the best prevention. Our 45 vaccines help protect people from 20 infectious diseases, including cervical cancer, liver cancer, tuberculosis, poliomyelitis, rabies, measles, yellow fever, shingles and influenza. Our vaccines help protect everyone throughout life – from infancy to old age. Sanofi Pasteur MSD is a joint venture between sanofi pasteur - the vaccine division of sanofi-aventis - and Merck & Co. Inc. We develop, license, market and distribute vaccines in Western Europe. We lead the vaccine industry in Western Europe. Together with sanofi Pasteur and Merck we are working to make vaccines available to more people in the developing world, in alliance with organisations such as the World Health Organisation (WHO) and the Global Alliance for Vaccines and Immunisation (GAVI).

Cepheid is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company’s solutions deliver a better way for institutions of any size to perform sophisticated genotyping testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, in fields such as critical and healthcare-associated infections, sexual health, genetic diseases and cancer.

Hologic is committed to improving lives through the development of premium diagnostic solutions, medical imaging systems and surgical products. The company offers fully automated instruments and in vitro nucleic acid testing for STIs, including the highly sensitive and specific APTIMA assays for chlamydia, gonorrhoea, trichomoniasis and HPV. These best-in-class tests run on Hologic’s fully automated instrumentation, including the Panther system – combining all aspects of nucleic acid testing on a single, integrated platform.

As the world leader in in vitro diagnostics, Roche offers a broad portfolio of instruments and assays for the screening, diagnosis and prevention of infectious diseases. With an ongoing focus on patient needs and the depth and breadth of our comprehensive portfolio, Roche is your partner for improving patient outcome by offering a wide range of solutions to Microbiologists, Clinical Researchers and Infection Preventionists. Visit our booth for the latest molecular, PCR-based assays and proven immunochemistry innovations.
Astellas Pharma is dedicated to improving the lives of people around the world through providing innovative and reliable pharmaceutical products. Our declared aim is to become a global category leader in a number of therapeutic areas in which further innovation can fulfill unmet patient needs. Astellas’ key strengths lie in the therapy areas of Transplantation, Urology, Dermatology, Anti-Infectives, Pain Management and Oncology. Astellas’s philosophy is to contribute unceasingly to the health of people around the world by providing innovative and reliable pharmaceutical products.

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people’s health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

Standard Diagnostics, Inc. has developed and supplied over 100 premium-quality products for malaria, HIV, dengue, and syphilis to more than 160 countries around the world. SD works closely with international organizations such as WHO, and UNICEF, as well as government procurement agencies and overseas distributors – supplying its products to more than 160 countries around world.

MSD, one of the leading pharmaceutical companies in the world, is paving the way to a healthier future with products that touch the lives and improve the well-being of people and communities around the world. The company product portfolio is among the broadest in the healthcare industry. As a leader in global healthcare, MSD is committed to addressing critical social, environmental and economic challenges as well to ensure the health of our world.

Greiner Bio-One is an internationally leading technology partner for academia and research institutes as well as the diagnostic, pharmaceutical and biotechnology industry. The company is specialised in the development of innovative molecular biology analysis methods. These include DNA microarray-based diagnostic assays combining a large number of biological or biochemical tests in a compact space, e.g. the PapilloCheck® and PapilloCheck® high-risk test systems for the detection of different HPV types.

Meda is an international specialty pharma company with own operations in 50 countries. Meda holds a well-diversified product portfolio, has a global presence, and is represented in all pharmaceutical areas: Specialty Products, Branded Generics, and OTC. Meda focuses mainly on five key therapy areas: dermatology, respiratory, cardiology, pain and inflammation, and CNS. For more information visit www.meda.se
The STI & AIDS World Congress gratefully acknowledges the support of the following exhibitors (as per date of printing June 2013)

In alphabetical order:

Abbott
BD Diagnostics
Bio-Rad
BMJ Publishing Group
BZgA (Bundeszentrale für gesundheitliche Aufklärung Aidsprevention und Internationale Beziehungen)
Cepheid
Copan Italia
DiaSorin
ECDC (European Centre for Disease Prevention and Control)
Gilead Sciences
Greiner Bio-One
Hologic
Invitalis
MEDA Pharma
Mikrogen
MSD
NIH AIDS Research Programs
Omega Diagnostics
Qiagen
Randox Laboratories
Roche Molecular Systems
Seegene
Sekisui Diagnostics
Standard Diagnostics
Wisepress
WHO (World Health Organization)

Opening Hours Exhibition:

Sunday, July 14, 2013  9:30 - 18:00 hrs.
Monday, July 15, 2013  9:30 - 18:00 hrs.
Tuesday, July 16, 2013  9:30 - 18:00 hrs.
Wednesday, July 17, 2013  9:30 - 18:00 hrs.
We are pleased to invite you to the World STI & AIDS Congress 2015 to be held in Brisbane, Australia. This congress will be a collaboration of ISSTDR/IUSTI but will also be held in conjunction with the Australasian Sexual Health Conference run by the Australasian Sexual Health Alliance.

You will also benefit from the opportunity of attending the Australasian HIV&AIDS Conference (16-18 September) which has run back-to-back with the Sexual Health Conference in Australia for many years.

We look forward to seeing you in Australia.

Professor Basil Donovan,
Chair of the World STI & AIDS Congress 2015,
President of ISSTDR

Professor David Lewis,
Co-Chair of the World STI & AIDS Congress 2015.

www.worldsti2015.com